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ABSTRACT 
The in vitro 02 chromosomal radiosensitivity assay is a technique used to investigate 
variation in the cellular response to radiation. In brief, lymphocytes are irradiated in the 
02 phase of the cell cycle to induce DNA damage, which is exhibited at the subsequent 
metaphase as chromatid gaps and breaks. Radiation-induced arrest at the end of (32  is 
believed to allow time for adequate DNA repair before the onset of mitosis. Therefore, 
variation in the level of aberrations observed at metaphase is likely to be driven in part 
by 02 checkpoint control. This led to an investigation into whether variation in in vitro 
G2 chromosomal radiosensitivity is related to 02 checkpoint efficacy. 
A modified version of the 02 chromosomal radiosensitivity assay was validated with 
samples from staff at Westlakes Research Institute. The standard 02 assay protocol was 
altered by the addition of the chemical calyculin A which induces Premature 
Chromosome Condensation (PCC) in interphase cells enabling visualisation and 
classification of all cell cycle stages ((ii,  S, 02 and metaphase). Initial attempts at 
assessing 02 to metaphase transition by visualising and scoring damage directly in 02 
cells failed. However, by measuring changes in the ratio of PCC-02 and metaphase 
cells before and after irradiation, it was possible to measure 02 checkpoint delay. 
Following validation of the PCC technique, both the 02 assay and the modified assay 
were applied to a group of 29 cancer survivors and the extent of any individual 02 
checkpoint delay was compared to the radiation-induced chromatid aberration 
frequency. 
No significant relationship between chromatid aberration frequency and (32  checkpoint 
delay was observed. Providing that the PCC technique is accurately assessing 02 delay, 
Ill 
the results suggest that variation in 02 chromosomal radiosensitivity is more likely to be 
driven by variation in DNA repair pathways than variation in 02 checkpoint delay. 
iv 
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CHAPTER 1 
INTRODUCTION 
Scope of Study 
In vitro assays have demonstrated that cells from cancer prone human genetic 
syndromes and, indeed, cancer itself exhibit elevated sensitivity to the DNA-damaging 
agent radiation. One such assay is the in vitro chromosomal radiosensitivity technique, 
in which the amount of radiation-induced chromosome damage observed in metaphase 
cells is used as a measure of radiosensitivity. In addition to cellular sensitivity, 
exposure to ionising radiation is known to cause delay in the cell replication cycle. 
Such checkpoint delay is thought to allow time for genome repair before the onset of 
replication or mitosis i.e. at G/S borders and 02/M transition, respectively. Therefore, 
variation in the level of chromosome damage observed at metaphase is likely to be 
driven in part by checkpoint control (Scott et al 2003; Terzoudi and Pantelias 1997; 
Terzoudi et al 2005; Zampetti-Bosseler and Scott 1981). 
This thesis describes the application of a technique called Premature Chromosome 
Condensation (PCC), which can be used to directly enumerate cell cycle perturbation 
following radiation exposure, in conjunction with the established in vitro chromosomal 
radiosensitivity assay (Scott et a!, 1996; Smart et a!, 2003). The hypothesis tested by 
this work was that an increase in delay before the onset of mitosis (G2IM checkpoint) is 
directly correlated with a visible reduction of chromosome damage in metaphase. The 
work herein discusses the initial attempts at using the PCC technique in the Westlakes 
Research Institute (WRI) laboratory and then goes on to describe the application of this 
methodology to a Danish population of 30 survivors of childhood and young adulthood 
cancer. 
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The results failed to provide evidence that checkpoint delay is associated with 
chromosomal radiosensitivity, at least in this particular cancer survivor cohort. The 
thesis concludes with a discussion of the possible reasons for these findings, limitations 
of the assays employed, the importance of intra-individual variation, further work which 
may be useful and the influence of age, gender and cancer type. 
1 INTRODUCTION 
1.1 CHROMOSOMAL RADIOSENSITIVITY 
1.1.1 Human Genetic Syndromes 
A number of human genetic disorders with diverse clinical outcomes have been 
identified that predispose the individual to a high risk of developing cancer and which 
exhibit chromosomal instability e.g. Ataxia telangiectasia (AT), Bloom's syndrome 
(BS) and Fanconi's anemia (PA). Collectively, they have been termed chromosome 
breakage syndromes (Carney 1999; Futaki and Liu 2001). 
AT is an autosomal recessive disorder estimated to occur in approximately I in 100,000 
live births in the USA (Swift eta! 1986) and 1 in 300,000 in Great Britain (Woods eta! 
1990). Clinical manifestations of this childhood disease include progressive 
immunodeficiency, neurological degeneration (ataxia) and dilated blood vessels 
(telangiectasia) in the corners of the eyes or on the surface of the ears and cheeks 
(reviewed by Chun and Gatti 2004). Approximately, 25% of those with AT develop 
cancer, most frequently acute lymphocytic leukaemia or lymphoma; this high cancer 
predisposition may be linked to a decreased capacity to repair DNA damage. 
Radiosensitivity in AT was first described in two young individuals treated for cancer 
by means of radiotherapy (Gotoff et a! 1967; Morgan eta! 1968). Two boys aged 9 and 
10 years suffered severe adverse reactions to radiation treatment, including dermatitis, 
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necrosis, dysphagia, and progressive respiratory collapse. The unexpected tissue 
responses ultimately led to death within four and eight months, respectively. This 
abnormal sensitivity to radiation leading to enhanced cell killing was confirmed in vitro 
by exposing AT fibroblast cells lines to y-radiation (Taylor et al 1975). Further studies 
demonstrated an enhanced sensitivity to X-ray irradiation which manifests itself as 
increased chromosomal damage compared to controls (Bender et al 1985; Nagasawa et 
al 1985; Natarajan and Meyers 1979; Taylor 1978). An enhanced sensitivity to 
radiation, using the endpoint of chromosomal aberrations, has also been observed in BS 
(Aurias et a! 1985; Kuhn 1980; Parshad et al 1983) and FA (Bigelow et al 1979; 
Higurashi and Conen 1973; Parshad et a! 1983). However, the results of many 
investigations into the chromosomal radiosensitivity of chromosome breakage 
syndromes were inconclusive and difficult to reproduce with only AT patients 
consistently demonstrating radiosensitivity outside of any control population (reviewed 
by Murnane and Kapp 1993). 
1.1.2 The Cell Cycle Based 62 Chromosomal Radiosensitivity Assay 
In vitro cellular radiosensitivity of cultured cells can be detennined using a variety of 
assays which test for endpoints such as cell death, mutagenicity, cell cycle perturbation, 
chromosome damage, and DNA damage/repair. The cell cycle based in vitro G2 
chromosomal radiosensitivity assay has been one of the most commonly used protocols 
for the last 30 years and has provided good discrimination in radiation response between 
individuals. The cell cycle consists of four distinct phases termed gap 1 (C1), synthesis 
(S), gap 2 (02) and mitosis. In G1. a high level of protein synthesis occurs and the 
chromosomes are prepared for S phase, in which duplication of cellular DNA occurs. 
Following successful DNA replication a short 02 phase of 4 - 5 hours exists to allow 
preparation for mitosis, in which cells divide. 
The in vitro 02 chromosomal radiosensitivity assay can be performed on any dividing 
cell population, i.e. either cell lines or on stimulated blood lymphocytes. In brief, the 
assay involves irradiating PHA-stimulated peripheral blood lymphocytes or fibroblast 
cell lines in vitro to induce DNA damage. A short time for normal repair processes is 
allowed, before the extent of unrepaired damage, in the form of chromatid gaps and 
breaks, is measured at metaphase (Figure 1.1). Thus, only cells that were in the 02 
phase at the time of irradiation are sampled by this protocol. The earliest applications of 
the assay were used to demonstrate that AT cells are abnormally radiosensitive in the 02 
phase of the cell cycle (Rary et a! 1974). In the late 1970's this cytogenetic assay was 
further developed and utilised in a number of studies at the National Cancer Institute 
(NC!), Bethesda, USA by Katherine Sanford and colleagues. Many early studies 
sampled skin fibroblasts, but difficulties such as bacterial contamination and long pre-
culture growth times (Sanford et a! 1989), led to the 02 assay being adapted for 
lymphocytes obtained from a peripheral blood sample (Sanford et a! 1990). Between 
1983 and 1997 the NC! group demonstrated elevated 02 chromosomal radiosensitivity 
in a large number of cancer-prone syndromes including FA, familial polyposis coli and 
BS (Parshad et a! 1983); chronic ulcerative colitis (Sanford et a! 1997b); Down's 
syndrome (Sanford et at 1993); familial dysplastic naevus syndrome (Sanford et a! 
1997a); Gardner's syndrome (Parshad et a! 1983; Takai et a! 1990); xeroderma 
pigmentosum (Parshad et at 1983; Price et a! 1991), Li-Fraumeni syndrome (Parshad et 
al1993) 
  and AT homozygotes (Sanford et at 1990). 
Many studies have attempted to discriminate between AT heterozygotes, AT patients 
and normal controls using radiation-induced chromatid aberrations as their endpoint 
(Bender eta! 1985; Parshad eta! 1985; Sanford eta! 1990; Shiloh eta! 1986; Shiloh et 
FE 
al 1989; Tchirkov et a! 1997). These studies produced conflicting results and the 
present consensus is that radiosensitivity, as measured by induced chromatid 
aberrations, is an unsuitable endpoint for carrier detection due to considerable overlap 
between AT heterozygotes and the normal populations. Despite the findings of some 
groups, the International Commission on Radiological Protection (ICRP 1998) advise 
that the only cancer-prone syndromes with definitive elevated G2 radiosensitivity are 
AT homozygotes and Nijmegan breakage syndrome (NBS) (Weemaes et a! 1981), 
which was originally thought to be a variant of AT. 
David Scott and colleagues at the Paterson Institute for Cancer Research (PICR) in 
Manchester applied the NCI assay to control and cancer-prone individuals in an attempt 
to confirm the clear discrimination previously found at the NCI between the two groups 
(Scott et a! 1996). A comparison of control donors at the NCI and PICR uncovered 
more inter-experiment variability in the PICR control group coupled to clear differences 
in aberration yields, kinetics of aberration decline and mitotic inhibition. The 
experimental variability demonstrated by the PICR group when applying the NC! assay 
was eventually resolved. Scott and colleagues (1996) were able to demonstrate that a 
centrifligation step prior to irradiation was slowing the progression of some cells into 
metaphase and the harvesting of cells at 37°C was allowing chromosomal repair 
thi-oughout the harvesting procedure. By omitting the centrifugation step and harvesting 
cells at 0°C to stop repair, experimental variability was reduced. Even with these 
changes, PICR researchers were unable to repeat the results of the NCI group in being 
able to discriminate between cancer predisposed groups and controls, with complete 
discrimination only found between controls and AT homozygotes (Scott ci a! 1996). 
Having established the assay, the PICR laboratory began large-scale investigations into 
radiosensitivity and predisposition to common cancers. 
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Figure 1.1: The G2 chromosomal radiosensitivity assay. The cell cycle consists of four 
distinct phases termed gap 1 (Gi).  synthesis (S), gap 2 (02) and mitosis. Mitosis is sub-
divided into prophase, metaphase, anaphase and telephase. Cells not undergoing the 
four stages of mitosis may also be referred to as interphase cells. Gap 0 cells are 
quiescent, hence not taking part in the cell cycle. PHA-stimulated peripheral blood 
lymphocytes are irradiated and after a short interval of I .5h, to allow (32  cells to 
progress to mitosis, the cells are harvested. Chromatid aberrations, indicated here by 
blue arrows, are viewed in metaphase after cell harvesting and slide preparation. The 
numbers of chromatid aberrations in 50 or 100 cells are totalled to produce a "02" 
radiosensitivity score. 
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1.1.3 C2 Chromosomal Radiosensitivity and Cancer 
Although many early 02 chromosomal radiosensitivity studies concentrated on cancer-
prone families, there was a clear interest to research cancer predisposition in 
conjunction with 02 chromosomal radiosensitivity in sporadic cancer patients (without a 
strong family history) with the aim of uncovering genetic markers and evaluating 
predictive tests. Significantly elevated radiosensitivity has been reported in cells from 
patients with a diverse range of cancers although results have conflicted between 
laboratories. A list of the studies undertaken to date is provided in Table 1.1. 
To investigate whether individuals with sporadic breast cancer exhibit enhanced 02 
chromosomal radiosensitivity, the 02 assay was applied to a population of sporadic 
breast cancer patients in two studies at the PICR (Scott eta! 1994a; Scott eta! 1999). A 
comparison of 02 scores between a control population of 105 donors and 135 breast 
cancer patients revealed that approximately 40% (53/135) of breast cancer patients 
exhibit an elevated chromosomal radiosensitivity compared to 6% of control individuals 
(Scott et a! 1999) (Figure 1.2). To discriminate between a sensitive and normal 
response Scott and colleagues utilised a cut-off value at the 90th 
 percentile in the control 
distribution and applied this value to the breast cancer patients. Although, this 90 th  
percentile value was, to some extent, arbitrary, it resulted in good discrimination 
between populations and has since been adopted in the majority of 02 chromosomal 
radiosensitivity studies. Earlier studies using fibroblasts utilised a variety of techniques 
and often sampled only small numbers of individuals. The work of Scott and colleagues 
was significant in that it was the largest study of its type at the time and the 02 assay 
had been standardised for use with peripheral blood lymphocytes to give more 
reproducible results. 
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Table 1.1 G2 chromosomal radiosensitivity in cells from cancer patients. 
Cancer Type 	 Normal sensitivity' 	 Elevated sensitivity2 
Breast 	 Docherty eta! 2007 	 Baria et a! 2001; Baeyens et 
a! 2002; Howe et a! 2005b; 
Parshad et a! 1996; Patel et 
a! 1997; Riches et a! 2001; 
Scott et a! 1 994a; Scott et a! 
1999; Terzoudi et a! 2000 
Brain 	 Terzoudi et a! 2000 
Bladder 	 Terzoudi et a! 2000 
Head and Neck 	 Papworth eta! 2001 	 Papworth eta! 2001 
(age of diagnosis? 45)  (age of diagnosis S 45) 
De Ruyck eta! 2008; 
Terzoudi et a! 2000 
Colorectal 	 Baria eta! 2001; Darroudi et 
a! 1995 
Cervical 	 Baria eta! 2001 	 Terzoudi eta! 2000 
Lung 	 Baria eta! 2001 	 Terzoudi eta! 2000 
Prostate 	 Howe et a! 2005a 
Paediatric and Adolescent 	 Curwen et a! 2005 3 Baria et a! 2002; Curwen et 
(treated S 20 years). 	 a! 2005 
Includes Hodgkin's disease, 
non-Hodgkin's lymphoma, 
osteosarcoma, Wilms' 
tumour, 
Rhabdomyosarcoma. 
Retinoblastoma Darroudi eta! 1995 	 Sanford eta! 1996 
Skin Terzoudi et a! 2000 
Leukaemia Terzoudi et a! 2000 
Lymphoma Darroudi et a! 1995 
Wilms' tumour Darroudi eta! 1995 
1,2 
 Normal and elevated sensitivity designated on the basis of standards defined within 
individual studies. 
on control group used as comparison. 
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Figure 1.2: ( 2 chromosomal radiosensitivity of a group of normal donors (top) and a 
group of breast cancer patients (bottom). The solid line is at the 90th 
 percentile value of 
the control group and indicates the cut-off point between sensitive and non-sensitive 
individuals. Adapted from Scott eta! (1999) and Scott (2004). 
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Epidemiological data suggest that 4 - 13% of breast cancer patients could be carriers of 
the mutated AT gene (Easton, 1994) and this may contribute to the enhanced sensitivity 
seen in a population profile. However, the enhanced radiosensitivity observed in over 
40% of breast cancer patients could not be attributed to the small percentage of AT 
heterozygotes within the sporadic breast cancer population studied. For this reason, it 
was postulated that genetic predisposition to breast cancer may be the result of 
mutations in genes of a low penetrance involved in the processing of DNA damage, and 
is not confined to those with a strong family history such as carriers of the ATM gene 
and individuals with BRCAJI BRCA2 mutations (Scott et a! 1999; Scott et a! 2000; 
Scott 2004). As further evidence, the University of (ihent (Belgium) laboratory failed 
to demonstrate a role for either BRCA] or BRCA2 (heterozygous carriers) in conferring 
G2 chromosomal radiosensitivity (Baeyens et a! 2004). This suggests that the 
contribution of BRCA1/2 towards sporadic breast cancer is perhaps minimal, although a 
more recent report showed that healthy BRCA 1 carriers had significantly more 
radiation-induced chromatid aberrations compared to controls matched for age, sex and 
ethnicity (Barwell et a! 2007). Epidemiological evidence supporting the hypothesis of 
Scott includes studies of cancer incidence in twins (Lichtenstein et a! 2000; Peto and 
Mack 2000) which indicate that breast cancer, in the majority of cases, arises in 
genetically predisposed females and cannot be accounted for by relatively rare 
mutations in BRCAJ or BRCA2. This finding further supports the concept that other low 
penetrance genes, as yet unidentified, confer an enhanced radiosensitivity. Candidates 
for low penetrance cancer-predisposition genes include CHEK2 (Meijers-Heijboer et a! 
2002) and polymorphisms in microsatellites associated with DNA repair genes such as 
XRCCJ, XRCC2 and XRCC3 (Price eta! 1997). 
Since the breast cancer study of Scott was published in 1994, a number of independent 
studies have reported significantly elevated G2 chromosomal radiosensitivity in breast 
nm 
cancer (Baeyens et a! 2002; Baria et a! 2001; Howe et a! 2005b; Parshad et a! 1996; 
Patel et a! 1997; Riches et a! 2001; Terzoudi et a! 2000). However, a more recent study 
of 211 newly diagnosed breast cancer patients in conjunction with 170 age, sex and 
ethnically matched controls revealed no significant difference in levels of chromatid 
breaks between patients and controls (Docherty et al 2007). The fact that this study 
failed to replicate the findings of David Scott's group, as well as other groups, was 
surprising but may be explained in part by the choice of assay employed. Docherty et a! 
(2007) modified the method of Howell and Taylor (1992) which is routinely used at 
Guy's Hospital to aid the diagnosis of radiosensitivity in patients with phenotypic 
features of AT and NBS. The Howell and Taylor technique has some differences to the 
method developed by Scott and colleagues. For example, cell harvesting was carried 
out at room temperature which may facilitate further rejoining of chromatid gaps and 
there were minor differences in scoring criteria. 
Encouraged by the promising findings of the breast cancer studies, a number of studies 
investigated whether chromosomal radiosensitivity was associated with other cancer 
types (Baria et a! 2001; Baria et a! 2002; Curwen et a! 2005; De Ruyck et al 2008; 
Howe et a! 2005a; Papworth et a! 2001; Terzoudi et a! 2000). A large-scale study 
compared G2 chromosomal radiosensitivity in 25 normal individuals with a group of 
185 cancer patients containing a variety of malignancies including breast, cervix, 
prostate, larynx, lung, brain, bladder, skin and leukaemia (Terzoudi et a! 2000). For all 
cancer types, the mean radiation-induced chromatid aberration yields were higber than 
in the normal individuals and the average sensitivity of the cancer patients, taken as a 
whole, was significantly greater than the control group (P = 0.001). An examination by 
the PICR group into colorectal cancer, lung cancer and cancer of the cervix as well as in 
chronic disease (diabetes mellitus and non-malignant lung disease) revealed that 30% 
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(12/37) of colorectal cancer patients exhibited an enhanced sensitivity, which was 
statistically significant (P = 0.01), when compared to the control population (Baria eta! 
2001). Unlike the study of Tcrzoudi et a! (2000), elevated 02 chromosomal 
radiosensitivity was not found in lung and cervical cancer. Again adopting the 90th 
percentile cut-off, the proportion of radiosensitive cases in lung cancer was only 23% 
(8/35) and in cancer of the cervix 11% (3/27) of patients were sensitive, values that 
were not significantly different. Both lung cancer and cancer of the cervix have a well 
established environmental aetiology with lung cancer strongly linked to tobacco 
smoking and cervical cancer linked to infection with human papilloma virus. The lack 
of a significant elevated radiosensitivity in these malignancies could be explained by the 
strong environmental aetiology and a far weaker inherited component in comparison 
with breast cancer. The existence of a genetic predisposition to cancer which is not 
linked to the repair of radiation induced damage, for example carcinogen metabolism, 
would not be detectable by the 02 assay and may provide an alternative explanation. 
There is some epidemiological evidence of an inherited component in colorectal cancer 
(Cannon-Albriglit a' a! 1988; Lichtenstein et a! 2000) and an elevated chromosomal 
radiosensitivity of 30%, may well be a marker of low penetrance genes. Another 
important finding was that patients with chronic disease (diabetes mellitus and non-
malignant lung disease) did not exhibit an enhanced radiosensitivity with only 12% 
sensitive compared to 9% in normals (Baria a' a! 2001). This indicates that elevated 
radiosensitivity may not be conferred by a diseased state itself. 
Continuing their work on cancer patients, the PICR group applied the 02 assay to a 
cohort of patients with head and neck cancer (Papworth et a! 2001). Using the 90th 
percentile cut-off, 31% (13/42) of patients were sensitive compared to 15% of normals 
but this was not statistically significant. However, when the patients were divided into 
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early onset cases (age of diagnosis 45) and normal onset (age of diagnosis ~ 45) the 
difference between the normal and the early-onset group was statistically significant 
with enhanced radiosensitivity in the early-onset group. The authors suggest that for 
early-onset cases there is a genetic predisposition which is not present in older patients. 
A more recent study revealed that 26% of head and neck cancer patients (age range 33 - 
91) were significantly radiosensitive compared with only 9% of healthy controls (De 
Ruyck et al 2008). The results of Papworth et a! (2001), were corroborated by the 
finding that head and neck cancer patients aged S50 years had the highest mean 02 
scores with a mean aberration frequency of 1.32 breaks per cell compared to 1.18 breaks 
per cell in patients aged >70 (De Ruyck et a! 2008). Environmental risk factors such as 
smoking and alcohol consumption are thought to predominate in older patients. Early-
onset cases represent less than 5% of all head and neck cancers (Camiol and Fried 1982; 
Decroix and Ohossein 1981; Son and Kapp 1985), so taken as a whole these studies 
suggest that head and neck cancer has a smaller genetic component in terms of 
predisposition, than breast cancer. 
1.1.4 Early-Onset Cancer 
The early onset of malignancy is thought to be a common feature in cancers that have a 
high inherited risk. Elevated radiosensitivity has been demonstrated in a mixed group 
of paediatric cancer patients when compared to age-matched controls (Baria et al 2002). 
When 32 early-onset cases, diagnosed before the age of 20 (age range 0.5 - 19), were 
compared to 41 young controls (age range 0.25 - 19) and 32 adult normals (age range 20 
- 
60) the authors found that 44% of patients were sensitive compared to 15% in young 
controls and 10% in adult controls. The results of this study hinted that a proportion of 
early-onset cancers may be driven by mutations in genes of low penetrance. 
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The 02 assay developed at the PICR was applied, with some minor changes, in our 
laboratory at WRI to investigate the association of 02 radiosensitivity with cancer 
predisposition and the heritability of the trait in a population of Danish survivors of 
childhood and adolescent cancer and their offspring (Curwen et a! 2005). In total, four 
groups were scored for G2 chromosomal radiosensitivity; 23 survivors of childhood and 
adolescent cancer, a control group comprising their 23 partners, 38 offspring and an 
internal control group consisting of 27 volunteers collected at WRI. When the 90th 
percentile cut-off of the WRI control group was implemented, the proportion of 
radiosensitive cases was 35% for the partners, 52% for the survivors and 53% for the 
offspring. There were no significant differences between WRI controls and Danish 
controls but significant differences between WRI controls and Danish cancer survivors 
(P = 0.002) and WRI controls compared with offspring (P c  0.001). However, when 
the 90' percentile cut-off for the Danish partner control group was applied, no 
significant differences were observed between the three Danish groups, with only 4% of 
cancer survivors and 18% of offspring found to be sensitive (Figure 1.3). The higher 
than expected proportion of radiosensitive individuals seen in the partner control group 
in comparison with the WRI control group could not be easily explained. Although the 
authors suggested there was a possibility that partners of cancer survivors may not be an 
appropriate control group, they concluded it was unlikely that the partners would form a 
distinct group with elevated radiosensitivity. The inability to distinguish between 
cancer survivors and their partner controls suggests that any association between 
elevated G2 chromosomal radiosensitivity and childhood cancer predisposition should 
be regarded with caution. Moreover, the WRI controls may not be an appropriate group 
for comparison with childhood and adolescent cancer. That being the case, the inability 
of the study to distinguish between cancer survivors and cancer partners seems to 
contradict the earlier findings by Baria et a! (2002). 
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Figure 1.3: Distributions of G2 chromatid aberration frequencies in WRI controls, 
partner controls, cancer survivors and offspring of cancer survivors. The vertical lines 
represent the cut-off points for a nonnal and radiosensitive response, based on the 90th 
percentile of the WRI control (red-dotted line) and partner control (solid black line) 
groups. Figure adapted from Curwen et al (2005) and reproduced with kind permission. 
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1.2 THE INFLUENCE OF RADIATION ON CELL CYCLE 
KINETICS 
1.2.1 Cell Cycle Control 
Cell cycle control is maintained by checkpoints at (i1/S transition and G2/Mitosis 
transition and is regulated by key proteins such as p53, ATM, BRCAI and various 
Cyclin Dependent Kinase (CDK) molecules. The G checkpoint exists to prevent cells 
from entering DNA synthesis with DNA damage which can then become 'fixed' in the 
genome. At this stage cells may be temporarily stopped from dividing and enter a state 
of quiescence called Go phase. The G2 checkpoint prevents the proliferation of 
damaged cells and allows time for DNA repair before transition to metaphase. Efficient 
cell cycle control is crucial for maintaining genomic integrity and stability, thereby 
preventing unregulated cell proliferation which leads to cancer. 
1.2.2 The Effect of Radiation upon the Cell Cycle 
Since the 1920's it has been recognised that radiation can affect cellular growth 
(Mottram et a! 1926). By 1953 an accurate representation of cell cycle progression was 
established using radiolabelling of S phase cells with 32P (Howard and Pelc 1953). 
Howard and PeIc discovered that X-ray irradiation prolonged both the Gi  and 02 phases 
and later work utilising HeLa cells revealed this delay to be dose-dependent (Yamada 
and Puck 1961). Such cell cycle delays are now thought to represent a co-ordinated 
cellular response to radiation in order to prevent damaged cells from progressing 
through the cell cycle. Investigations into 02 checkpoint delay utilising mutant cells of 
Saccharomyces cerevisiae that are unable to arrest in response to irradiation revealed 
that the observed cell cycle defect was also coupled to an increased radiosensitivity 
(Weinert and Hartwell 1988; Weinert 1992; Weinert et a! 1994). The authors postulated 
that cells contain checkpoints which arrest in response to DNA damage and that these 
checkpoints exist to allow time for DNA repair. 
22 
1.2.3 ATM Function in Cell Cycle Checkpoints 
ATM kinases are vital components of the pathway which controls DNA repair (Jeggo et 
cii 1998) and the length of the 02 phase (Shackelford et a! 1999). Due to the lack of 
functional ATM kinase in cells from AT patients, this group is a vital source for 
enabling a thorough exploration of the role of ATM kinase in DNA repair and cell cycle 
checkpoint processes. Investigations into the role of ATM in checkpoint function have 
produced a range of apparently conflicting results. For example, some studies have 
shown that AT cells fail to arrest at the 02 checkpoint after irradiation and progress 
immediately into metaphase (Beamish et al 1996; Scott et cii I 994b; Zampetti-Bosseler 
and Scott 1981), whilst other studies suggest a prolonged 02 arrest compared to normal 
cells (Beamish et a! 1994; Beamish and Lavin 1994; Scott et cii 1994b). These 
apparently opposing viewpoints may be explained by the existence of two distinct G2 
arrest mechanisms (Xu et cii 2002). Utilising a variety of cell cycle assays the authors 
demonstrated that a transient ATM-dependent checkpoint is activated shortly after 
irradiation to prevent damaged cells, irradiated in the 02 stage of the cell cycle, from 
progressing to metaphase. The second mechanism is measurable several hours after 
irradiation and is represented by the accumulation of cells in 02 phase that were 
irradiated in the S or G phase of the cell cycle. Crucially, this mechanism appears to be 
ATM independent, hence the accumulation of both AT and normal cells irradiated in the 
earlier stages of the cell cycle. 
1.2.4 Measuring G2 Arrest 
The total length of the 02 phase in irradiated lymphocytes and controls can be estimated 
using a number of techniques such as [ 3H]TdR labelling (Pincheira eta! 1994; Pincheira 
et a! 2001), fluorescence-activated cell-sorting (FACS) (Bates and Lavin 1989; 
Herzenberg eta! 2002; Hong eta! 1994; Hues a! 2001; Hu eta! 2002) and 5-bromo 2'- 
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deoxyuridine (BrDU) incorporation (Palitti et cii 1999). 02 checkpoint delay has been 
considered from a chromosomal radiosensitivity perspective using the mitotic index 
(MI) as a measure of the proportion of cells reaching mitosis. Mitotic inhibition (Mm) 
is calculated as the percentage reduction in the MI in irradiated cell cultures compared 
to non-irradiated cultures. It is postulated that Mln could be used as a reliable indicator 
of 02 checkpoint efficacy providing that MIn values are truly representative of mitotic 
delay. Lymphocytes from 20 donors were used to investigate the presence of an X-ray 
induced adaptive response, sensitivity to X-ray irradiation in 02 phase and 02 
checkpoint response (Pretazzoli et al 2000). Checkpoint activation was tested at both 
0.020y and 0.30y and was measured by MI (as a % of control) and labelling with 
[31-I]TdR. One donor in particular consistently exhibited a strong reduction in MI in 
combination with low breakage frequency. The reduction in MI may represent a longer 
period of 02 delay allowing more time for the repair of damage and thus, fewer 
aberrations are observed at metaphase. When the data for all twenty donors was 
analysed an increase in chromatid breaks was associated with a decrease in mitotic 
delay induced at 0.020y but not at 0.30y. 
To evaluate the 02 checkpoint efficacy of cells with a known checkpoint defect, Mm 
was used to determine the extent of cell cycle delay induced by X-ray irradiation in 02 
phase in a selection of AT homozygotes, AT heterozygotes and a control population 
(Scott et cii I 994b). The mean inhibition for control samples was calculated at 88.1% 
compared to 44.2% in AT homozygotes whilst heterozygotes demonstrated similar 
levels of inhibition (88.5%) to controls. These results suggest that AT cells, on average, 
have lower levels of 02 checkpoint delay compared to normal healthy individuals 
following radiation exposure in the 02 phase of the cell cycle. These findings were 
consistent with earlier studies based upon MI measurements, all of which demonstrate 
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that irradiation in 02 results in less delay in AT cells than controls (Hansson et al 1984; 
Mozdarani and Bryant 1989; Scott and Zampetti-Bosseler 1982). The group of Scott et 
a! (2003) also calculated Mln in 129 breast cancer patients and 105 normal controls, 
which were originally processed for the 02 assay (chromatid aberrations reported in 
Scott et a! 1999). Inhibition in the breast cancer patients was significantly lower 
compared to female controls (P = 0.009) suggesting decreased 02 checkpoint efficacy in 
patients compared to female controls. The authors suggest that this reduction in MIn 
may contribute to the enhanced chromosomal radiosensitivity of these patients, by 
allowing less time for the repair of chromatid damage before it is fixed and viewed in 
metaphase. 
1.2.5 PCC (Premature Chromosome Condensation) 
Chromatin condenses during the mitotic phase of the cell cycle in a highly ordered pre-
determined fashion. However, using molecular techniques, chromosome condensation 
can be uncoupled from mitotic events and be induced prematurely in cells in the 
interphase stage of the cell cycle. Originally, this was achieved by the deliberate fusion 
of interphase cells to mitotic cells using Sendai virus (Johnson and Rao 1970), later 
improved using polyethylene glycol (PEO)-mediated fusion (Pantelias and Maillie 
1983), and can now be achieved by the addition of the phosphatase inhibitors calyculin 
A or okadaic acid (Ootoh et a! 1995). PCC enables categorisation of each cell cycle 
phase due to the visualisation of distinct morphologies: O phase chromosomes are 
univalent, S phase cells are pulverised in appearance and 02 phase chromosomes are of 
similar appearance to those in metaphase in that they contain bivalent condensed 
chromosomes but can be distinguished due to the absence of a visible centromeric 
region (Ootoh et al 1995; Hatzi eta! 2007; Hatzi eta! 2008; Terzoudi et a! 2005). 
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Early application of the PCC technique revealed that arrested 02 cells repair many of 
their DNA breaks before mitosis (Hittelman and Rao 1974) indicating that one of the 
purposes of 02 delay is to allow time for the repair of DNA damage. Therefore, the 
efficacy of the 02 to metaphase checkpoint could influence the 02 radiosensitivity score 
measured at metaphase. The PCC technique has recently been combined with a version 
of the 02 radiosensitivity assay to investigate the role of the 02 checkpoint in the repair 
of DNA double-strand breaks (DSBs), in normal and AT cells (Terzoudi et al 2005). In 
this protocol the effect of complete checkpoint abrogation upon chromatid aberration 
burden was directly measured by comparing aberration levels in both normal and AT 
lymphocytes before and after 02 to mitosis transition. The key finding of this work was 
that there was no discernable difference in the number of chromatid breaks scored 
directly in artificially condensed 02 phase AT and normal cells prompting the authors to 
suggest that DNA DSBs are repaired in AT and normal cells with similar kinetics, and 
that the differences in frequencies of chromatid breaks in normal and AT cells is 
primarily due to the 02 checkpoint difference. Analysis of normal cells at metaphase 
revealed a two- to three-fold reduction in the number of breaks in comparison to 02 
phase whilst AT cells did not exhibit any strong reduction in chromatid aberration level. 
To confirm that normal cells exhibit a two- to three-fold reduction in chromatid damage 
following checkpoint transition, the 02 checkpoint was artificially abolished using 
caffeine, which acts as an ATM inhibitor. Following caffeine addition the number of 
chromatid aberrations in metaphase in normal cells was similar to that observed in AT 
cells. These investigations provided direct evidence that activation of the ATM-
dependent 02 checkpoint following irradiation is a key event in the reduction of 
chromatid damage observed at metaphase. In addition to analysing chromatid damage, 
this group calculated the ratio of cells in 02 to cells in 02 and metaphase in an attempt 
to measure the level of 02 delay following irradiation. An increase in this ratio was 
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observed in normal and AT heterozygote cells whereas there was no change in this ratio 
for AT homozygotes following irradiation. This was further proof that AT cells are 
unable to undergo checkpoint activation in response to irradiation in G2 phase. This 
laboratory has also used PCC methodology to evaluate the combined effects of radiation 
and the potential mutagens hydroquinone (Hatzi et cii 2007) and glutaraldehyde (Hatzi 
et al 2008) upon cell cycle progression and chromosomal radiosensitivity. These 
studies suggest that the direct enumeration of each cell cycle phase is a promising 
indicator of G2 checkpoint delay. 
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1.3 SCOPE AND AIMS OF THIS PROJECT 
The Genetic Consequences of Cancer Treatment study is a multi-national collaboration 
between research groups in the U.S.A, U.K., Denmark and Finland which utilise 
epidemiology, molecular genetic techniques and cytogenetics. The objective is to 
investigate whether preconception radiotherapy and chemotherapy received by children 
and young adults contribute to adverse pregnancy outcomes (Boice et al 2003) 
(http://www.gcct.org/)
. Pilot studies using blood of Danish trios (cancer survivor, 
partner and offspring) attempted to elucidate whether minisatellite mutations are 
indicative of transmissible radiation-induced damage (Rees et al 2006) and if 
chromosomal radiosensitivity is a marker of cancer predisposition (Curwen et a! 2005). 
The initial pilot study using blood has now been extended to further samples received 
from Danish families. This provided an opportunity to explore 02 chromosomal 
radiosensitivity in relation to 02 checkpoint function. 
In the first instance, development work to investigate the project viability using the PCC 
technique was undertaken employing samples from WRI staff. Once the methodology 
was fully developed, the technique was applied to a Danish population of 30 survivors 
of childhood and young adulthood cancer. The aim of this study was to apply PCC 
methodology in combination with the 02 radiosensitivity assay and to use this technique 
to investigate cell cycle perturbation following irradiation in relation to the frequency of 
chromatid aberrations observed at metaphase. Samples were cultured for the 02 and the 
02 + PCC assay to determine the 02 radiosensitivity score and 02 checkpoint delay, 
respectively. Any correlations between the two sets of data were investigated in the 
hope of illuminating the relationship between 02 checkpoint control and 02 
chromosomal radiosensitivity. 
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CHAPTER 2 
VALIDATION OF THE PREMATURE 
CHROMOSOME CONDENSATION 
(PCC) TECHNIQUE 
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2.1 INTRODUCTION 
Initial experiments were performed employing a group of healthy volunteers to ensure 
that the technique described in the literature could be performed in the WRI laboratory 
before commencing a study of cell cycle perturbation in cancer survivors (see Section 
3). The initial goal was to observe chemically-induced PCC in peripheral blood 
lymphocytes, to study chromosome morphology, assign cell cycle stage and to score 
chromatid aberrations directly in 02 phase as achieved by Terzoudi et al (2005) and 
Febrer et at (2008). 
2.2 METHODS 
2.2.1 Validation Study Population 
Samples were taken from WRI staff willing to volunteer blood. One individual donated 
blood on more than one occasion. All volunteers gave written informed consent before 
a blood sample was taken (see Appendix A for copy of consent form) and blood 
samples were coded to ensure anonymity. Slides made from these blood cultures were 
further coded by a member of staff not directly involved in the study to prevent scorer 
bias. As the majority of the volunteers also gave blood as part of the WRI 02 assay 
validation study (Smart et at 2003) or the Danish Trio Pilot study (Curwen et at 2005) 
the same coding system was adopted. In total seven donors participated, comprising of 
four males and three females. 
2.2.2 Sample Collection 
All samples were collected at WRI by a principal genetic counsellor. Blood was drawn 
into 5 ml lithium heparin vacutainers (BD Vacutainer Systems, Ref. 367684) and 
allowed to stand overnight at room temperature. 
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2.2.3 Cell Culture 
For each blood sample two 125 cm 3 
 culture flasks (VWR International Ltd, Catalogue 
No. 734-0031) were set up. The day before culturing, the volume of RPMI- 1640 
medium (Sigma®, Catalogue No. R8758) which was required for the particular sample 
size was supplemented with 15% foetal calf serum (Invitrogen Corporation, Catalogue 
No. 10099-133), 1% phytohaemagglutinin (M-form) (GibcoTM, supplied by Invitrogen 
Corporation, Catalogue No. 10576-015) and 1% L-glutamine (Invitrogen Corporation, 
Catalogue No. 25030-032). A single foetal calf serum batch (Lot. 495 5944s) was used 
for all samples throughout the validation work and the Danish cancer survivor study. 
The culture medium was placed in a 37°C, 5% CO2/95% air incubator and left overnight 
to pre-warm and undergo gaseous exchange. For each culture flask, 1 ml of blood was 
added to 9 ml of complete culture medium in a T25 cm 3 culture flask. All culture flasks 
were mixed gently and then placed upright in the incubator with the caps loose. The 
time of culture set up was then noted to keep to the strict timings required for this 
procedure. After exactly 48 hours of culturing 7 ml of the spent medium was removed 
using pre-warmed pipettes, taking care not to disrupt the cell layer. This medium was 
replaced with 7 ml of fresh pre-warmed, pre-gassed medium and the flasks were mixed 
by gentle inversion before been placed back into the incubator with the caps loose. 
2.2.4 X-ray Irradiation 
At 15 min prior to irradiation, flasks were gently mixed and placed in a 37°C portable 
incubator and transported by car to the X-ray facility (Siefert), located on the Westlakes 
Science Park in the Geoffrey Schofield Laboratories a short distance away 
(approximately ¼ mile). The X-ray set was maintained by regular warm-up operations 
and tested to ensure safety and the correct dose delivery. Before sample irradiation the 
31 
X-ray room was pre-wanned using a radiator and the set itself was warmed-up using a 
pre-programmed procedure. After exactly 72 hours total culture time, the flasks were 
either irradiated with 0.5 Gy 300kV X-rays or 'mock-irradiated' i.e. treated in an 
identical manner to the irradiated culture flasks apart from receiving X-rays. The dose 
received varied marginally between irradiated culture flasks with all exposures in the 
range 0.49-0.51 Gy. The exact dose was recorded for each sample. 'Mock-irradiated' 
control flasks were simultaneously removed and returned to the incubator with the 
corresponding irradiated flasks, but were not irradiated. This 'mock-irradiation' 
ensured identical treatment of both control and irradiated cultures. Each culture flask 
was outside the portable incubator for the shortest period possible to minimise any drop 
in temperature. Following irradiation, flasks were transported back to the laboratory 
and placed back in the incubator. After a recovery period of exactly 30 mm, lOOpl of 
pre-warmed KaryoMax colcemid ® (10 pgmU') (Invitrogen Corporation, Catalogue No. 
15210-057) was added to the culture flasks, which were then mixed gently by inversion 
and returned to the incubator. Colcemid enabled the collection and visualisation of 
chromosome spreads at metaphase by blocking mitosis via inhibition of spindle 
formation. 
2.2.5 PCC Induction 
The 02 assay was combined with PCC methodology in a protocol based on the study by 
Terzoudi et al (2005) (see Figure 2.1). The protocol adopted for PCC induction 
followed the methodology of the 02 assay with the exception that calyculin A (Sigma®, 
Catalogue No. C5552-10UG) was added in addition to colcemid. Three time points for 
the addition of calyculin A were tested to establish optimum conditions for PCC 
induction, visualisation of chromatid damage and good discrimination between 02 and 
metaphase spreads. At either 30 mm, 60 min or 75 min post-irradiation, 5i.il of 
calyculin A (0.1 mM) was added to the culture flasks, which were then mixed and 
returned to the incubator as before. 
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Figure 2.1: The protocol for evaluating PCC induction. PHA-stimulated peripheral 
blood lymphocytes were cultured for 72 hours using standard techniques with a media 
change at 48 hours. At 72 hours cultures were irradiated with 0.50y X-rays, colcemid 
was added at 30 miii post-irradiation which was 1 hour prior to cell harvesting. The 
time point of calyculin A addition was attempted at 3 time-points: 30 mm, 60 min and 
75 min post-irradiation. 
34 
2.2.6 Cell Harvesting 
Almost 90 min after irradiation, the contents of each culture flask were transferred to 
centrifuge tubes (Barloworid Scientific Limited, Catalogue No. 144A5) before being 
plunged into ice chippings at exactly 90 min post-irradiation. The tubes were left for 2-3 
min to facilitate rapid cooling to approximately 0°C to prevent further DNA repair. 
Tubes were then spun at 400 g in a pre-cooled centrifuge (0°C-4°C) for 5 mm. 
Following centrifugation, the supernatant was aspirated within 1.5 ml of the pellet and 
the cells were then vortexed before treatment with cold potassium chloride (KCI) 
solution (VWR International Ltd, Catalogue No. 101984L) for 20 min with regular 
inversion of tubes. After 5 min of centrifligation at 400 g cells were fixed slowly with a 
mixture of methanol (VWR International Ltd, Catalogue No. 10158 613) and acetic acid 
(VWR International Ltd, Catalogue No. 10001 CU) in the ratio 3:1, respectively. After a 
further centrifugation and fix, cells were stored at -20°C. The following week, these 
cell pellets were washed and fixed a further four times (six in total) and stored for a 
minimum period of 24 hours before making slides. 
2.2.7 Slide Preparation and Staining 
SuperFrost® 
 Slides (Scientific Laboratory Supplies, Catalogue No. M1C3024 and 
M1C3022) were cleaned with methanol, washed briefly under tap water and plunged 
into ice chippings for 30-60 min prior to preparing cell suspension. Meanwhile, 
centrifuge tubes containing cell pellets and fixative were removed from the -20°C 
freezer and left on the laboratory bench to equilibrate to room temperature for 30-60 
mm. To prepare the cell suspension, fixed cells were centrifuged at 400 g for 5 mm. 
After centrifugation, cells were re-fixed once as described in Section 2.2.6. The 
supernatant was completely aspirated making sure not to remove any cellular material 
and a further 0.5-1 ml of fresh fixative was added to create a milky suspension. Next, 
40 gI of cell suspension was dropped from a height of approximately 30-50 cm onto 
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cold, wet slides which were immediately passed through a flame. This technique of 
edge flaming was vital in producing evenly distributed chromosome spreads throughout 
the slide, which also had good quality morphology. Low humidity had been shown 
previously to adversely effect chromosome spreading and thus slides were often made 
over a sink of steaming water, no slide making was attempted when the humidity of the 
laboratory was below 40%, and the air conditioning was switched off. When dry, slides 
were arranged in glass troughs and stained with Giemsa stain solution (improved R66), 
(VWR International Ltd, Catalogue No. 350864X) diluted 1:19 with Gun ® buffer (1 
tablet supplied by BDH Limited dissolved in 11 H20) and air-dried. Once completely 
dry, slides were mounted by applying DPX mountant (VWR International Ltd, 
Catalogue No. 360294H) onto coverslips (20 x 50mm) (VWR International Ltd, 
Catalogue No. 631/0137) and firmly placing the slides on top ensuring air bubbles were 
eradicated. 
2.2.8 Microscopy 
Prior to scoring, all slides were scanned using the Metasystems Metafer4 scanning 
system which comprises a Zeiss Axioplan 2 imaging microscope with a Marzhauser 
motorized scanning stage connected to Metafer 4.MSearch software (Metasystems, 
Germany. www.metasystems.de ), (see Appendix B for photograph). This software and 
microscope package enabled the user to search an entire slide, to record and 
subsequently capture images of any cells which appeared to have 'metaphase-like' 
morphology. For automated pinpointing of each metaphase, mounted and coded slides 
were fixed into the microscope bays to allow for scanning at xlO magnification. This 
automated system had a few key advantages over standard light microscopy. Slides 
with low numbers of chromosome spreads could be identified immediately following 
scanning and discarded in favour of superior slides or more slides could be made if 
required. The speed of cytogenetic analysis was increased approximately two-fold 
because thumbnail images of poor quality spreads could be discarded prior to scoring 
and the user could move from cell to cell immediately with a mouse click instead of 
manually scrolling through an entire slide. 
To greatly improve the correct identification of cells that have visible chromosome 
spreads, as opposed to intact cells or non-nuclear material, the image capturing 
mechanism was trained using built-in software. This classifier training was used to set 
parameters for future scans and make the scanning process more efficient. In brief, the 
Metafer4 scanning system was used to capture a large number of images, which were 
then used to define objects, in this case metaphase spreads. A number of slides were 
scanned using a default classifier and a number of image fields were captured. At this 
stage, the computer was not used to do any automated analysis to recognise metaphase 
spreads. Instead, these training fields were reviewed manually. If a metaphase was 
present, the field was marked as 'Positive' and a green circle was drawn around the 
metaphase; everything not marked was recorded as 'Negative'. Objects that showed 
some characteristics of metaphase but were incomplete metaphases or non-cellular 
material such as 'dirt' were rejected by drawing a red circle around them. More than 
600 metaphases from several slides were required to fully train the software and create a 
fully functional classifier. A new classifier called 'G2 metaphases' was created and the 
command 'Compute Classifier' was initiated. The computer was left overnight to 
compute the classifier to complete the training. This new classifier was selected when 
scanning all the Danish trio slides. Following training, the number and quality of 
spreads identified increased greatly. 
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2.3 RESULTS 
2.3.1 The Effect of Calyculin A upon Chromosome Morphology 
The number, morphology and distribution of chromosome spreads varied substantially 
between samples for a variety of reasons, which may include intrinsic cellular 
characteristics, thickness of cell suspension used and slide making technique. Using the 
definitions and photos provided by others (Febrer et a! 2008; (Jotoh et al 1995; 
Terzoudi et al 2005; Hatzi et a! 2007; Hatzi et a! 2008) an attempt was made to 
distinguish between cells in G, S, 02 and metaphase. Examples of the types of cell 
morphology visualised are shown in Figures 2.2, 2.3, 2.4, 2.5 and 2.6. 01 phase cells 
often take the form of a condensed metaphase-like shape containing univalent 
chromosomes, whilst S phase cells take a 'pulverised' form and the chromosomes have 
thick and thin sections to them (Gotoh et a!, 1995). 02 phase PCC cells contain bivalent 
condensed chromosomes which are similar in shape to metaphase chromosomes. 
However, the key difference is that the two sister chromatids have no visible 
centromeric region conferring a distinctive morphology, easily distinguished from 
metaphase spreads (Flatzi et a! 2007; Hatzi et a! 2008; Terzoudi et a! 2005). 
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Figure 2.2: Chromosome spread with characteristics of PCC-G1 phase. These cells 
often take the form of a condensed metaphase-like shape containing 46 univalent 
chromosomes. In this and subsequent figures in Chapter 2, the photographs are of cells 
from the 7 different subjects used in the validation study population (n = 7). 
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Figure 2.4: Panels A-D are cells containing chromosome spreads with characteristics of 
PCC-G2 
 phase. These cells contain bivalent condensed chromosomes. The two sister 
chromatids have no visible centromeric region conferring a distinctive morphology, 
easily distinguished from metaphase spreads. Panels A and B have clearly visible sister 
chromatids. Panels C and D are PCC-G 2 cells containing tangled and overlapping 
chromosomes. Panels A-D are typical of 7 such experiments using the validation study 
population (n = 7). 
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Figure 2.5: Chromosome spreads with characteristics of metaphase. These cells 
contain bivalent condensed chromosomes with a visible centromeric region conferring a 
distinctive morphology. Typical of 7 such experiments using the validation study 
population (n = 7). 
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Figure 2.6: Miscellaneous chromosome spreads. Typical of 7 such experiments using 
the validation study population (n = 7). 
Panel A and B: Spreads contain more than 46 chromosomes, which are often smaller 
than seen in other spreads. Panel C: Chromosome spread showing the typical features 
of endoreduplication, a cell cycle defect found in cells released from 02 arrest in order 
to undergo mitotic catastrophe. Chromosome duplication without mitotic cell division 
results in multiple chromosomes. Panel U: Non-dividing Go cell. 
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The classification of cells into either PCC-01, PCC-S, PCC-G2 or metaphase is not 
always clear-cut, as some spreads appear to have characteristics of more than one phase. 
Late PCC-S phase cells, which have completed their DNA replication apart from a few 
chromosomal areas, often look like PCC-02 cells but contain more than 46 
chromosomes, have attenuated areas and many small breaks (email correspondence with 
Dr Gabriel Pantelias), (Figure 2.7). Upon the addition of calyculin A, these incomplete 
areas of replication condense and lead to breakage, explaining the high number of 
chromosome pieces observed. In contrast, PCC-G2 cells have thlly completed DNA 
replication and form sister chromatids without any visible discontinuity or areas of 
attenuation. 
Some of the cells visualised contained chromosomes with premature centromere 
division (PCD), (Figure 2.8). Although they share the key feature of PCC-G2 cells in 
that they contain no visible centromere they appear morphologically distinct. One of 
the effects of calyculin A addition seems to be an increase in PCD with reported rates of 
16-17% in amniotic fluid cultures and 10% in lymphocyte cultures (Srebniak et al 
2005). Although high levels of PCD in calyculin A treated cultures were not seen, these 
cells were more common than in colcemid only cultures. 
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Figure 2.7: Late PCC-S phase cells. Chromosome number is higher than 46. Arrows 
mark possible areas of incomplete DNA replication. Typical of 7 such experiments 
using the validation study population (n = 7). 
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Figure 2.8: Premature Centromere Division (PCD). Typical of 7 such experiments 
using the validation study population (n = 7). 
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2.3.2 Differentiation of PCC-G 2 and Metaphase Cells 
In initial attempts at differentiating between PCC-0 2 
 and metaphase, only cells with 
well spread chromosomes were included to maintain integrity in the scoring procedure 
(Figure 2.9). However, by leaving out many tight, unclear spreads which were most 
likely PCC-02 
 cells there may have been a danger of underestimating the number of 
cells in 02 phase in comparison to metaphase cells, which have, on the whole, an 
unambiguous morphology. The cell cycle is a continuous process and some cells, 
which are likely to be close to transition points, display characteristics of both S and 02 
phase or both 02 and metaphase. Due to the presence of such cells in combination with 
tight overlapping chromosomes, the classification of cell cycle stage was more difficult 
than at first anticipated. Crucially, the definition of what comprised a PCC-0 2 phase 
cell was decided upon before embarking on the Danish cancer survivor samples and 
strict criteria were applied throughout that part of the study to both control and 
irradiated cultures. Examples of cells included and excluded in analysis are shown in 
Figures 2.10, 2.11 and 2.12. 
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Figure 2.9: PCC-G2 cell from an unirradiated sample with good spreading, two clearly 
visible sister chromatids and no visible centromerie region. Typical of 7 such 
experiments using the validation study population (n = 7). 
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Figure 2.11: PCC-0 2 cell. Despite overlapping and difficulty in differentiating sister 
chromatids the cell contains bivalent chromosomes with no visible centromeric region. 
In the scoring criteria chosen such cells would be classed as PCC-G 2 cells. Typical of 7 
such experiments using the validation study population (n = 7). 
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Figure 2.12: Cells with characteristics of both PCC-Ci 2 and metaphase. Due to the 
presence of centromeric constriction in many of the chromosomes these cells would be 
scored as metaphase cells in the scoring criteria chosen. Typical of 7 such experiments 
using the validation study population (n = 7). 
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2.4 DISCUSSION 
2.4.1 Timing of Calyculin A Incubation 
Studies which have used the chemically-induced PCC technique in conjunction with the 
02 chromosomal radiosensitivity assay have added calyculin A at either 60 mm (Febrer 
et al 2008; Terzoudi et al 2005) or at 75 mm (Shovman et al 2008) post-irradiation. 
This current study undertook a small number of experiments to assess three prospective 
time points at 30 mm, 60 min and 75 min post-irradiation. Addition of calyculin A at 
75 min post-irradiation failed to produce many discernible PCC-G2 cells in the slides 
examined. The addition of calyculin A at 75 min post-irradiation i.e. 15 min pre-
harvest, has recently been combined with 02 assay methodology in an attempt to 
improve the traditional colcemid-only assay (Shovman et a! 2008). The authors 
describe a substantial decrease in cells with split centromeres in comparison with longer 
calyculin A incubation times. In addition, the mitotic index was higher and thus, an 
increase in scorable condensed chromosome figures was observed. However, to assess 
the 02 checkpoint in the first few hours after irradiation it is vital that the assay 
employed can distinguish mitotic cells from 02 cells (Xu et al 2002). For this study, 
differences in centromeric constriction, as applied by Terzoudi et a! (2005), were used 
to distinguish between metaphase and G2 cells. Based on the limited data, the 75 mm 
post-irradiation time did not allow visualisation of such morphological differences and 
therefore was not suitable for this specific project. 
The addition of colcemid and calyculin A together at 30 min post-irradiation resulted in 
the vast majority of cells resembling PCC-G2 spreads making a comparison of PCC-02 
to metaphase ratio difficult. By delaying the addition of calyculin A for another 30 mm 
and instead adding at 60 min post-irradiation, more 02 cells are allowed to pass into 
metaphase before artificial condensation of the entire cell population. Therefore, the 60 
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min post-irradiation time enables visualisation of a substantial number of both PCC-G 2 
and metaphase cells and thus, an accurate evaluation of any change in the ratio of PCC-
02 to metaphase cells can be calculated. In addition, the 60 minute post-irradiation 
timing enabled visualisation of chromatid damage within a proportion of these 
irradiated cells. In line with the protocol of other groups (Febrer et al 2008; Terzoudi et 
al 2005) the 60 min post-irradiation timepoint was adopted. 
2.4.2 Scoring Chromatid Aberrations in the G2 Phase of the Cell Cycle 
One of the original aims was to score chromatid aberrations in PCC-G 2 cells. 
Unfortunately, there was limited success. Few PCC-G 2 cells with good spreading in 
combination with clear sister chromatids were observed which made scoring gaps and 
breaks far more difficult than in cells routinely seen in metaphase. When scoring was 
attempted extra care was taken when analysing PCC-G 2 cells. Only PCC-G 2 cells which 
had good quality morphology comparable to metaphase cells were analysed (Figure 
2.13). Chromatid aberrations were only recorded if visible as sharp breaks which were 
almost certainly caused by X-irradiation rather than unclear areas of attenuation, faded 
bands or scratches produced by coverslip damage, incomplete DNA replication or any 
other disruption to cell morphology. By obtaining a digital image of individual cells 
using a microscope mounted camera in conjunction with an image analysis software 
package called Interactive KARy-Otyping System (IKAROS), (Metasystems, 
Germany) and applying sharpening filters, it is possible to improve the visualisation of 
damage. However, this is a time consuming process and the morphology must still be 
of a reasonable standard. To maintain integrity, the analysis of manipulated images, as 
opposed to the scoring of actual cell damage visualised using microscopy, should be 
undertaken with caution. 
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A number of laboratories employing the PCC technique for the study of chromatid gaps 
and breaks before the onset of mitosis have utilised cell lines or isolated lymphocytes 
rather than peripheral blood cultures (Bryant et a! 2008; Gotoh et a! 1995; Gotoh eta! 
1999; Hittelman and Rao 1974; Terzoudi et a! 2000; Terzoudi and Pantelias 1997; 
Wang et a! 2006). However, there have been some recent successes in scoring 
chromatid damage directly in (32  phase by adding calyculin A to peripheral blood 
cultures (Febrer et a! 2008; Terzoudi et a! 2005). Further work would be useful to 
assess the visualisation of damage in both cell lines and in blood cultured lymphocytes 
to confirm which cell type allows accurate analysis. 
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Figure 2.13: Aberrations observed in a PCC-0 2 cell following 0.5Gy X-ray irradiation. 
Red arrows show chromatid gaps and breaks. Typical of 7 such experiments using the 
validation study population (n = 7). 
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2.5 CONCLUSIONS 
The results have shown that the methodology implemented enabled chemically-induced 
PCC to be observed in peripheral blood lymphocytes. PCC was investigated as a 
technique for studying perturbation in the (32 cell cycle checkpoint in a group of healthy 
volunteers. Unfortunately, direct analysis of chromatid aberrations in the 02 phase 
proved unreliable. Following a number of failed attempts to visualise and accurately 
score damage directly in PCC-0 2 cells the decision was taken to instead score the ratio 
of cells in each cell cycle stage before and after irradiation. By calculating the ratio of 
PCC-G2 cells versus PCC-0 2 + metaphase cells before and after the 02 to mitosis 
transition point, it was possible to measure the extent of any radiation-induced 02 
checkpoint delay. The next stage was to apply the PCC technique to a group of Danish 
cancer survivors to assay radiation-induced G2/mitosis cell cycle perturbation and make 
direct comparisons to 02 chromosomal radiosensitivity measured in metaphase. 
14.1 
CHAPTER 3 
EXAMINING G2 CHROMOSOMAL 
RADIOSENSITIVITY AND CELL 
CYCLE 	 PROGRESSION 	 IN 
CHILDHOOD 	 AND 	 YOUNG 
ADULTHOOD CANCER SURVIVORS 
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3.1 INTRODUCTION 
Following the establishment of optimum conditions for PCC induction in the WRI 
laboratory and the determination of practical scoring criteria, the 02 assay and the 02 + 
PCC assay were applied to survivors of childhood and young adulthood cancer. The 
relationship between chromatid aberration frequency, as determined by the (32  assay, 
and cell cycle perturbation, as determined by the 02 + PCC assay, was investigated. 
The UCLan Faculty Ethics Committee was able to register as an approved Institutional 
Review Board who reviewed and approved the overall project. In addition, ethical 
permission was obtained in Denmark from the Danish Scientific Ethical Committee and 
the Danish Data Protection Agency, as well as, the Westlakes Ethics Committee. 
3.2 METHODS 
3.2.1 The Cancer Survivor Group 
Dr Jeanette Falck-Winther (Institute of Cancer Epidemiology, Danish Cancer Society, 
Copenhagen, Denmark. http://www.cancer.dk/epi%20research/) 
 was the co-ordinator 
for family selection, sample collection and transport for the Danish blood studies 
section of the Genetic Consequences of Cancer Treatment project (www.gcct.org ). 
In Denmark, a national Central Population Register (CPR) was established in 1968 
based upon a personal identification number for each citizen. This information can be 
linked to population-based health registries including the Danish Cancer Registry, the 
Danish Central Cytogenetic Registry, the Danish Medical Birth Registry and the 
Abortion Registry. Dr Jeanette Falck-Winther used these databases to target a suitable 
cohort of eligible survivors, spouses and offspring. Inclusion criteria required that 
patients were alive on, or born after, April 1968 when the national Central Population 
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Register (CPR) was established, were diagnosed with cancer at age <35 years between 
1943 and 2002, had survived until a fertile age of 15, had received moderate to high 
doses of scattered radiation to the gonads, had live offspring and were treated at either 
the Rigshospitalet (State Hospital) in Copenhagen or the Aarhus Kommunehospital 
(Community Hospital) in Jutland. Dr Faick-Winther contacted eligible survivors by 
letter to determine willing participants which produced a final study group of 30 Danish 
survivors of cancer. Information on cancer in relatives, cancer type, medical treatment, 
radiation exposure and aspects of lifestyle was obtained from a questionnaire and family 
health portrait completed by each survivor (see Appendix C for copy of questionnaire). 
To ensure anonymity each family was assigned a study number (T29 - T59) and the 
blood samples were labelled accordingly before being sent to WRI. This study 
continued the numbering system adopted for the pilot study of 28 Danish cancer trios 
(cancer survivor, partner and offspring) labelled TI to T28 (Curwen et al 2005). Blood 
samples from the partners and the offspring of the cancer survivors were also 
transported to WRI along with the survivors, as part of the over-arching study into the 
Genetic Consequences of Cancer Treatment (www.gcct.org ) but were not used in this 
project. 
3.2.2 Transport and Internal Assay Controls 
To monitor any intra-sample variability and provide data on any transportation effect 
two volunteers were sampled in Denmark on the same day as the family blood samples 
were drawn and set-up in culture for the (32  chromosomal radiosensitivity assay. The 
two volunteers were not related to the participating families and had no previous 
incidence of cancer or radiation exposure. In addition, one volunteer acted as an 
internal assay control and was sampled at WRI and cultured in parallel to the Danish 
transport controls and the Danish trios for both the 02 chromosomal radiosensitivity 
58 
assay and the (i2 + PCC assay. Details of sample collection for all three control samples 
are provided in Table 3.1. 
3.2.3 Sampling and Transport 
The WRI internal assay control, the two Danish transport controls, and the 30 cancer 
survivors together with their families provided written informed consent before a blood 
sample was taken (see Appendix A for copy of internal consent form and Appendix D 
for copies of Danish consent form and information leaflet). 
All Danish families and the two transport controls had peripheral blood drawn into 
lithium-heparin vacutainers at the State Hospital, Rigshospitalet, Copenhagen or the 
Skejby Hospital, Aarhus during the Monday of the sampling week. Blood was kept at 
room temperature prior to being shipped to WRI via courier. The internal WRI control 
was also sampled on the Monday of the sampling week and allowed to stand overnight 
at room temperature. The inclusion of a piece of dental X-ray film with each shipment, 
subsequently analysed by the Dosimetry Department at the Sellafield Nuclear 
Reprocessing Plant, Cumbria, U.K., revealed no evidence of radiation exposure during 
flight. All shipments were received by 8 am on Tuesday and cultures were set up in 
family groups at two or three time-points (depending on shipment volume) throughout 
the day to allow for manageable sample processing. Where possible, blood samples 
were set up in culture within 24 hours, with some samples set up between 24 and 28 
hours of being drawn. In total, 8 shipments containing 122 blood samples were 
transported to WRI between June and December 2006. Due to one of the survivor 
blood samples failing to culture the final analysed study group comprised a total of 29 
cancer survivors. Details of the cancer survivor group are provided in Table 3.2. 
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Table 3.2: Details of the cancer survivor group. 
Cancer Survivor ID Shipment Sex Age Age 
Date at sampling at diagnosis Cancer diagnosis (years) (years) 
2901 19/06106 M 41 26 Hodgkin's disease 
3001 19/06/06 M 45 13 Hodgkin's disease 
3101 26/06/06 F 47 17 Hodgkin's disease 
3201 26/06/06 F 32 1 Neuroblastoma 
3301 11/12/06 F 62 9 Non-Hodgkin's lymphoma 
3401 03/07/06 F 41 8 Non-Hodgkin's lymphoma 
3501 03/07/06 F 44 9 Non-Hodgkin's lymphoma 
3601 03/07/06 M 46 17 Non-Hodgkin's lymphoma 
3701 03/07/06 F 34 13 Hodgkin's disease 
3801 03/07/06 F 41 15 Hodgkin's disease 
3901 30/10/06 F 61 9 Non-Hodgkin's lymphoma 
4001 30/10/06 M 43 9 Non-Hodgkin's lymphoma 
4101 06/11/06 F 61 15 Hodgkin's disease 
4201 06/11/06 M 48 27 Hodgkin's disease 
4301 13/11/06 M 41 28 Hodgkin's disease 
4401 06/11/06 M 56 17 Non-Hodgkin's lymphoma 
4501 06/11/06 F 55 16 Non-Hodgkin's lymphoma 
4601 06/11/06 F 32 3 Wilms' tumour 
4701 13/11/06 M 43 30 Hodgkin's disease 
4801 13/I 1/06 M 52 19 Hodgkin's disease 
4901 13/11/06 M 47 28 Hodgkin's disease 
5001 13/11/06 M 38 3 Hodgkin's disease 
5101 13/1 1/06 M 60 10 Non-Hodgkin's lymphoma 
5201 04/12/06 M 50 14 Hodgkin's disease 
5301 04/12/06 M 68 32 Testis (seminoma) 
5401 04/12/06 F 54 16 Hodgkin's disease 
5501 04/12/06 M 61 24 Testis (teratoma) 
5601 04/12/06 M 55 28 Testis (seminoma) 
5701 11/12/06 M 58 30 Testis (teratoma) 
5801 11/12/06 M 52 24 Testis (seminoma) 
Mean 48.9± 1.74 17.0± 1.62 
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3.2.4 The 62 Chromosomal Radiosensitivity Assay 
The assay described herein, was based upon the method described by Scott et al (1996). 
Cell culture was carried out as described in Section 2.2.3 but with the following 
changes: For each cancer survivor two culture flasks were set up and labelled as 
assay irradiated' and 'G2 assay control'. For each culture flask 2 ml of blood was added 
to 18 ml of culture medium and the flasks were placed in the 37°C CO2 incubator for 72 
hours culture. After exactly 48 hours of culturing 15 ml of the spent medium was 
removed using pre-warmed pipettes, and this medium was replaced with 15 ml of fresh 
pre-warmed, pre-gassed medium. The flasks were mixed by gentle inversion before 
been placed back into the incubator with the caps loose. 
Samples were irradiated as described in Section 2.2.4. Following irradiation flasks were 
transported back to the laboratory and placed back in the incubator. After a recovery 
period of exactly 30 mm, 200 gI of pre-warmed KaryoMax colcemid ® was added to the 
culture flasks, which were then mixed gently by inversion and returned to the incubator. 
Cell harvesting and slide preparation and staining were carried out as detailed in 
sections 2.2.6 and 2.2.7, respectively. 
3.2.5 Scoring Metaphase Cells 
Prior to any actual sample analysis, each microscope user scored the same 50 cells from 
a sample collected for an earlier study. This scoring check ensured that the same 
scoring criteria were applied throughout the study and eliminated any scorer bias. Two 
Cytogeneticists, using either the Zeiss Axioplan 2 imaging microscope linked to image 
analysis equipment or a conventional Nikon ° halogen microscope, scored 50 cells per 
irradiated sample using different slides, giving a total of 100 scored cells. A Student t- 
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test was utilised to measure variation in the number of aberrations for each set of 50 
cells scored per sample. This monitoring method revealed that any fluctuation between 
analysts was non-significant (P = 0.86). 
Upon identif'ing a metaphase, an assessment was made on whether the cell was suitable 
for scoring. Cells were checked for reasonably well spread morphology and the absence 
of scratches. Cells that were discarded contained obviously fewer than 46 
chromosomes, had extremely compact morphology or contained many overlapping 
chromosomes. For the remaining cells, all chromosome pieces were counted and 
checked for one centromere per chromosome. If 46 chromosome pieces with only one 
centromere per chromosome were present, these cells were marked as normal and 
assessed for chromatid damage. Metafer 4.MSearch software was used to improve the 
efficiency of the manual microscope analysis by calculating the co-ordinates of each 
cell relevant to the user's microscope. Therefore, there was no need for the user to 
manually scroll through the whole slide for good quality chromosome spreads, which 
can be a time-consuming process. 
3.2.6 Assessment of Chromatid Damage 
Chromatid aberrations were scored using previously outlined criteria (ISCN, 1995) that 
have been applied in a number of studies (Curwen ci -il 2005; Scott ci al 1996; Scott ci 
al 1999; Smart ci al 2003). Chromatid gaps were defined as single aligned 
discontinuities larger than the width of a chromatid and chromatid breaks were defined 
as distinct dislocation and mis-alignment of the broken segments (Figure 3.1). For each 
sample, the number of gaps and breaks were combined to produce a total chromatid 
aberration yield. The other type of aberrations noted but not used to determine the G2 
radiosensitivity score were chromosome gaps and breaks defined as a break through 
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both chromatid arms (Figure 3.2). Gaps which were smaller than the width of a 
chromatid were also recorded but did not contribute to the overall aberration score. 
There has was some conifision in the classification of 'gaps' and 'breaks' with different 
laboratories using slightly different criteria. The scoring of chromatid aberrations was 
discussed in detail at a 02 assay workshop in 2001 (Bryant ci al 2002). Although some 
groups did score aberrations smaller than the width of a chsomatid, it was used as a 
measure of radiosensitivity (Vral ci a! 2002). It is likely that all types of discontinuities 
in a single chromatid arm were derived from DNA DSBs (Bryant 1984) and evidence 
obtained from correlating chromatid aberrations with the comet assay suggests that 
'small gaps' are indicative of DNA damage (Paz-y-Mino ci a! 2002). For this reason it 
was likely that these 'small gaps' were biologically significant and some laboratories 
believed that all visible discontinuities should compose the final 02 score (Bryant ci a! 
2002). It was demonstrated that the results obtained when scoring with and without 
small gaps were comparable although the variability was increased when gaps smaller 
than the width of a chromatid were included (Adema ci a! 2003). The authors 
speculated that the inclusion of small gaps might be less suitable for discriminating 
between individuals with small differences in chromosomal radiosensitivity (Adema ci 
a! 2003). The standard procedure at the WRI laboratory was to record data on 'small 
gaps' but to only publish 02 scores which comprised of clearly defined breaks and gaps 
larger than the width of a chromatid. 
It was common practice for induced aberration yields to be calculated by subtracting the 
number of chromatid breaks and gaps in control samples from those in the 
corresponding irradiated sample. Following a review of current data on spontaneous 
yields and data cited in many other studies, that laboratory at WRI stopped scoring 
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unirradiated samples. In control samples the number of chromatid aberrations was 
usually low (0 - 4 per 100 cells) and did not correspond to the sensitivity of an 
individual. This decision had substantially decreased the amount of time taken to 
analyse the cohort. Control cultures were still processed and are available for scoring if 
necessary. 
All results were recorded on the 'G2 Radiosensitivity Score Sheet' (Appendix E) either 
by hand or using the image analysis electronic form. On completion of sample analysis, 
all score sheets were audited to ensure that all additions were correct. 
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Figure 3.1: Chromatid aberrations observed in metaphase following 0.5Gy X-ray 
irradiation. The total aberration yield for this cell is four. (The small gap did not 
contribute to the G2 radiosensitivity score). Typical of 29 such experiments using the 
cancer survivor population (n = 29). 
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Figure 3.2: Metaphase from an irradiated peripheral blood culture containing a 
chromosome aberration. Both cluomatid arms are broken and mis-aligned. Typical of 
29 such experiments using the cancer survivor population (n = 29). 
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3.2.7 The G2 + PCC Assay 
The protocol adopted was a minor modification of the G2 chromosomal radiosensitivity 
assay which differed only by the addition of calyculin A. For this reason it was referred 
to as the G2 + FCC assay. For each of the 29 cancer survivors two culture flasks were 
set up and labelled as 'G2 + FCC assay irradiated' and 'G2 + PCC assay control'. The 
protocol followed was detailed in sections 2.2.3, 2.2.4, 2.2.5, 2.2.6 and 2.2.7. The 
chosen time point for calyculin A addition was at 60 minutes post-irradiation (see 
Section 2.3.3). A flow diagram in Figure 3.3 summarised the protocols for the G2 assay 
and the G2 + PCC assay. 
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One culture flask 	
0.5Gy 
irradiated 	 I 
	
G2 	 X-irradiation 	 One culture flask 	 I G2 + I FCC X-irradiation 
'mock-irradiated' 	 ______ 
4 	 4 
Addition of colcemid 	 Addition of colcemid 
4 
Addition of calyculin A 
60mm 
3Omir 
Chromatid aberration analysis 	 Cell cycle analysis 
S 
} 
'1 
~ @a -~ 	C I  'wi- G  Metaphase 
a. 
Figure 3.3: The procedure for the G2 assay and the G2 + PCC assay. n = 29 for cancer 
patients and n = 3 for healthy controls. 
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3.2.8 Measuring G2 Checkpoint Delay 
The automated image analysis machine was used to scan slides and pinpoint 
chiomosome spreads. All detected spreads were analysed sequentially under a xl 00 
lens. PCC-G2 cells, metaphase cells, PCC-G 1 
 phase cells, PCC-S phase cells and cells 
of an unknown origin were marked on the score sheet but only the PCC-G 2 and 
metaphase cells were used in the ratio calculation. For each sample, a combined total of 
at least 500 PCC-G2 and metaphase cells were recorded and used to calculate the ratio 
of PCC-G2 
 to metaphase cells before and after irradiation. 
The effect of irradiation on G2 checkpoint delay (A) was assessed by calculating the 
proportion of cells in G2 phase in irradiated cultures vs unirradiated cultures: 
]Un  Ir 
I 	 I 
A= 	
I 
I 	 I-I G2 +M 	 G2 +M 
Where 02 is the number of PCC-G 2 cells, M is the number of metaphase cells, Jr is the 
proportion of PCC-G2 
 cells relative to metaphase cells in the irradiated culture and Un is 
the proportion of PCC-G 2 
 cells relative to metaphase cells in the unirradiated culture. 
In contrast to the scoring of chromatid aberrations, all chromosome pieces were not 
counted, although it was still vital to check whether the cell appeared intact and had no 
obvious loss of chromosomes. For each sample, the ratio was recorded and calculated 
on an electronic form generated by the image analysis machine (see Appendix F). The 
extent of 02 checkpoint delay was compared to the 02 chromosomal radiosensitivity 
scores to examine any correlation. A strong correlation would suggest that cell cycle 
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delay, as measured by this technique, directly affects the level of chromatid aberrations 
at metaphase. 
3.2.9 Statistical Methods 
The distributions of chromatid gaps and breaks amongst metaphase cells were analysed 
for approximation to the Poisson distribution and standard errors were calculated taking 
into account overdispersion as described by Savage (1970) and applied previously at 
WRI (Smart et al 2003). The mean numbers of aberrations, the standard deviation, 
variance and the ratio of variance to mean were calculated for each donor. A ratio of 
variance to mean of one would be expected for a Poisson distribution which indicated 
that every cell had an equal chance of developing an aberration. A value of greater than 
one indicated that the distribution of aberrations in all samples was overdispersed. 
Inter-individual and intra-individual variation in aberration frequencies were examined 
by chi-squared (x2) analysis using the formula (2 = (O—E) 2/EZ) where 0 was the 
observed value of aberrations, E was the expected value of aberrations and Z was the 
overdispersion factor calculated as the average value of ratio of variance to mean. This 
analysis was carried out using Microsoft® 
 Excel and a P value was obtained using the 
CHIDIST command =CHIDIST(SUM, DF), where SUM is the sum total of all chi-
squared values for the population and DF was the total degrees of freedom. Percentage 
coefficients of variation (CV) were calculated by dividing the standard deviation by the 
mean. 
Standard errors were calculated by adjusting for overdispersion of chromatid-type 
aberrations using the appropriate overdispersion factor. The standard error for the 
cancer survivors was calculated according to the formula 'I(Total number of aberrations 
x Z)/Total number of samples taken. For internal and transport controls, where repeat 
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sampling had occurred, any additional intra-individual variation introduced was also 
compensated for. Standard errors for control samples were calculated according to the 
formula 'J(Mean no. of aberrations per sample x Z x Y)/ Total number of samples 
taken. Y was the sum of all the values of chi-squared divided by the total degrees of 
freedom. 
The Maim-Whitney U test was used to examine whether the probability distributions 
were equal in the two sets of data. The null hypothesis that observations in one group 
tend to be larger than observations in the other group was tested and a P value 
generated. In this project, the Mann-Whitney U test was used to compare the data sets 
for males and females and to examine differences in cancer types. Spearman's rank 
correlation analysis was used to test the null hypothesis that there were no relationships 
between data sets. Two columns of data were inputted into columns and ranked before 
analysis. A correlation coefficient (R) which falls between +1 and -1 was calculated 
which indicates the direction of correlation and its strength. An R value of -1 would 
indicate a strong negative correlation and an R value of +1 would indicate a strong 
positive correlation. A P value was then calculated to determine the significance level. 
For this project, Spearman's rank correlation analysis was used to examine the 
relationship between G2 chromosomal radiosensitivity and G2 checkpoint delay as 
measured by the G2 + PCC assay, as well as any influence of age. All analyses were 
performed using the Minitab statistical software package (www.minitab.cpp) andlor 
Microsoft® Excel. 
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3.3 RESULTS 
33.1 G2 Chromosomal Radiosensitivity in Internal Assay and Transport Controls 
Table 3.3 displays the frequencies of radiation-induced chromatid aberrations for all 
collected samples from the internal assay control and the two transport controls, in 
addition to their corresponding coefficient of variation. The average ratio of variance to 
mean for each control was 1.55 for the internal assay control, 1.78 for transport control 
1 and 1.45 for transport control 2. These results indicate that the distribution of 
aberrations in all the control samples is overdispersed. This result is consistent with the 
pilot Danish trio study carried out at the WRI which gave a ratio of variance to mean 
which was, on average, 1.5 (Smart et al 2003). To take into account any overdispersion 
the expected values for the yields of chromatid gaps and breaks per 100 metaphases 
were adjusted by a factor of 1.55, 1.78 and 1.45 for the internal assay control, transport 
control I and transport control 2, respectively. The mean radiation-induced chromatid 
aberration frequencies per 100 cells ± standard error were 113.57 ± 3.35, 131.29 ± 5.85 
and 124.80 ± 7.47 for the internal assay control, transport control 1 and transport control 
2, respectively. The coefficients of variation (CV) were calculated as 20.65%, 31.17% 
and 29.94% for the internal assay control, transport control 1 and transport control 2, 
respectively. Chi-squared analysis revealed statistically significant intra-individual 
variation for the internal assay control ()?6 = 18.74, P = 0.005), transport control 1 (y3 = 
42.95, P <0.001), and transport control 2 (x24 = 30.85, P <0.001). 
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33.2 The Relationship between C2 Checkpoint Delay and C2 Chromosomal 
Radiosensitivity in the Internal Assay Control 
This individual was sampled on seven occasions for the 02 assay and blood was 
cultured for both the 02 assay and the 02 + PCC assay on four of those occasions. Even 
though significant intra-individual variation was found for all seven samples, as shown 
in Section 3.3.1, when the four samples cultured for both the 02 assay and the 02 + PCC 
assay were analysed in isolation no significant intra-individual variation for 02 
chromosomal radiosensitivity was revealed ( = 4.70, P = 0.195), although a CV of 
14.67 was calculated. A scatter plot of the radiation-induced chromatid aberration 
frequencies and the corresponding 02 checkpoint delay for the four samples is 
illustrated in Figure 3.4. Although only four samples were taken a trend is suggested. 
1-lowever, Spearman's rank correlation analysis revealed there was no significant 
relationship between 02 checkpoint delay and radiation-induced chromatid aberrations 
in this individual (r = -0.800, P = 0.200). 
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Table 3.4: The radiation-induced chromatid aberration frequencies and the 
corresponding value of G2 checkpoint delay for the internal assay control. 
Sample Aberration 	 (%) G2 delay2 yield per 	 (A) 100 cells 
Spearman's 
rank 
correlation 
P4 
G2NN-1 	 132 	 -0.02 
G2NN-2 	 126 	 0.16 
14.67 	 -0.80 	 0.20 
G2NN-7 	 111 	 0.14 
G2NN-8 	 94 	 0.40 
'Coefficient of variation for G 2 radiosensitivity, 'G 2 delay (A) was determined by subtracting the 
proportion of PCC-G 2 cells relative to metaphase cells in the unirradiated culture from the proportion in 
the irradiated culture, 3Correlation coefficient for G 2 delay, 4Significance level achieved when using 
Spearman's rank correlation analysis. 
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Figure 3.4: Correlation between G2 checkpoint delay (A), as measured by the G2 + 
PCC assay, and chromatid aberration frequencies for the internal assay control. A is 
calculated by subtracting the proportion of PCC-G2 cells relative to metaphase cells in 
the unirradiated culture from the proportion in the irradiated culture. 
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3.3.3 The Relationship between G2 Chromosomal Radiosensitivity and G2 
Checkpoint Delay in the Cancer Survivor Group. 
Table 3.5 illustrates the radiation-induced chromatid aberration frequencies and the 
corresponding level of G2 checkpoint delay for the cancer survivor group. The average 
ratio of variance to mean for the cancer survivor samples was 1.73 indicating that the 
distribution of aberrations in all the cancer survivors is overdispersed. The mean 
aberration frequency was 137.21 ± 2.86 per 100 cells and a CV of 25.3% was 
determined for inter-individual variability. In addition, chi-squared analysis revealed a 
statistically significant difference between the samples at the 0.05 significance level 
0X228 =142.09, P c 0.001). The distribution of the radiation-induced chromatid 
aberration frequencies is in Figure 3.5. 
A scatter plot of the radiation-induced chromatid aberration frequencies and the 
corresponding G2 checkpoint delay for each sample is illustrated in Figure 3.6. No 
significant relationship was observed between G2 checkpoint delay and chromatid 
aberration frequency (r = -0.206, P = 0.284). 
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Table 3.5: Details of the cancer survivor group including radiation-induced 02 
aberration frequencies and the corresponding level of 02 checkpoint delay. 
Cancer 
Survivor 
ID 
Sex 
Age 
at sampling 
(years) 
Cancer diagnosis 
Aberration 
Yield per 
100 cells 
C2 delay 
2901 M 41 Hodgkin's disease 147 -0.20 
3001 M 45 Hodgkin's disease 102 -0.29 
3101 F 47 Hodgkin's disease 153 -0.10 
3201 F 32 Neuroblastoma 123 0.09 
3301 F 62 Non-Hodgkin's lymphoma 123 0.33 
3401 F 41 Non-Hodgkin's lymphoma 74 0.20 
3501 F 44 Non-Hodgkin's lymphoma 110 0.32 
3701 F 34 Hodgkin's disease 170 0.12 
3801 F 41 Hodgkin's disease 142 0.06 
3901 F 61 Non-Hodgkin's lymphoma 95 0.16 
4001 M 43 Non-Hodgkin's lymphoma 172 -0.25 
4101 F 61 Hodgkin's disease 114 -0.16 
4201 M 48 Hodgkin's disease 135 -0.19 
4301 M 41 Hodgkin's disease 127 0.08 
4401 M 56 Non-Hodgkin's lymphoma 107 0.10 
4501 F 55 Non-Hodgkin's lymphoma lOS -0.20 
4601 F 32 Wilms' tumour 183 0.27 
4701 M 43 Hodgkin's disease 98 0.32 
4801 M 52 Hodgkin's disease 204 -0.05 
4901 M 47 Hodgkin's disease 187 -0.08 
5001 M 38 Hodgkin's disease 124 0.05 
5101 M 60 Non-Hodgkin's lymphoma 180 -0.12 
5201 M 50 Hodgkin's disease 206 0.32 
5301 M 68 Testis (seminoma) 101 0.39 
5401 F 54 Hodgkin's disease 133 -0.18 
5501 M 61 Testis (teratoma) 113 0.06 
5601 M 55 Testis (seminoma) 134 0.20 
5701 M 58 Testis (teratoma) 165 0.04 
5801 M 52 Testis (seminoma) 152 0.26 
Median 
- 48 
- 133 0.05 
'G 2 
 delay (A) was determined by subtracting the proportion of PCC-G2 cells relative to metaphase cells in 
the unirradiated culture from the proportion in the irradiated culture. 
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Figure 3.5: Radiation-induced chromatid aberration frequencies in the cancer survivor 
group. Mean level of chromatid aberrations = 137.21 ± 2.86 per 100 cells, n = 29. 
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Figure 3.6: Correlation between 02 checkpoint delay (A), as measured by the 02 + 
PCC assay, and chromatid aberration frequencies in the cancer survivor group. A is 
calculated by subtracting the proportion of PCC-G2 cells relative to .metaphase cells in 
the unirradiated culture from the proportion in the irradiated culture, n = 29. 
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3.3.4 The Influence of Age, Gender and Cancer Type upon G2 Chromosomal 
Radiosensitivity and 62 Checkpoint Delay 
Spearman's rank correlation analysis revealed that there was no significant correlation 
between 02 chromosomal radiosensitivity and age (r = -0.207, P = 0.282) and no 
significant correlation between 02 checkpoint delay and age (r = 0.057, P = 0.767). A 
scatter plot of the age of each survivor at sampling and the corresponding chromatid 
aberration score is illustrated in Figure 3.7 and a scatter plot of the age of each survivor 
and the corresponding G2 delay value is shown in Figure 3.8. 
Comparison of data sets using Mann-Whitney U test revealed that there were no 
significant differences between genders for either 02 chromosomal radiosensitivity (P = 
0.241) or G2 checkpoint delay (P = 0.479) (Table 3.6). The distribution of radiation-
induced chromatid aberrations according to gender is illustrated in Figure 3.9. Figure 
3.10 shows a scatter plot of the relationship between 02 chromosomal radiosensitivity 
and 02 checkpoint delay according to gender. 
Dividing the cancer type into two groups as follows: haematological (Hodgkin's/non-
Hodgkin's) versus other cancers (testis/wilms'/neuroblastoma) resulted in no significant 
differences between the two groups for either G2 chromosomal radiosensitivity (P = 
0.879) or 02 checkpoint delay (P = 0.067) when using the Mann-Whitney U test (Table 
3.6). The distribution of radiation-induced chromatid aberrations according to cancer 
type is illustrated in Figure 3.11. Figure 3.12 shows a scatter plot of the relationship 
between 02 chromosomal radiosensitivity and 02 checkpoint delay according to cancer 
type. 
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3.4 DISCUSSION 
3.4.1 G2 Chromosomal Radiosensitivity in Internal Assay and Transport Controls 
Investigations into the effect of in vitro radiation exposure on cells from patients with 
cancer prone syndromes suggested that elevated G2 chromosomal radiosensitivity is 
associated with cancer predisposition (Bender ci al 1985; Parshad ci al 1983; Parshad ci 
al 1993; Rary ci' al 1974; Sanford ci al 1987; Sanford et al 1989; Sanford ci a! 1990; 
Shiloh ci a! 1989; Taylor ci al 1975; Taylor 1978). More recent studies have revealed 
elevated levels of chromatid damage in a variety of cancer types in comparison to 
healthy control groups (Baeyens ci al 2002; Baria ci a! 2001; Baria ci a! 2002; De 
Ruyck ci a! 2008; Howe ci a! 2005b; Papworth ci a! 2001; Parshad cia/1 996;   Riches ci 
a! 2001; Scoff ci a! I 994a; Scoff ci a! 1999; Terzoudi et a! 2000). Regarding assessment 
of cancer risk, the G2 chromosomal radiosensitivity assay has proved less useful in the 
clinical setting due to considerable overlap between patients and normal individuals in 
the vast majority of studies. This overlap, coupled to doubts regarding reproducibility 
of repeat samples, signifies that it may not be useful in determining risk at the individual 
level especially after only one blood sample (Vral ci a! 2002; Vral ci a! 2004). 
However, providing that the inter-individual variation exceeds the intra—individual 
variation, as shown by Scoff ci a! (1999), the G2 chromosomal radiosensitivity assay is 
still useful for providing quantification of risk in population based studies. 
It is widely recognised that the G2 chromosomal radiosensitivity assay is technically 
exacting and requires validating before setting up in the laboratory. In the WRI 
laboratory, G2 assay reproducibility of separate samples from the same donor was 
confirmed and revealed that intra-individual variation was non-significant for seven out 
of the nine healthy donors sampled (Smart ci a! 2003). However, x2  analysis revealed 
statistically significant variation in two of the donors, although removal of the highest 
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02 score sampling point for each of these donors resulted in non-significant variation 
(Smart et a! 2003). Similarly, in the 2005 Danish trio study that was undertaken at the 
WRJ laboratory, the intra-individual variation in the internal assay control was found to 
be non-significant and a CV of 13.56% was reported (Curwen et cii 2005). However, 
when this individual was sampled a further seven times, as part of this project, an 
increased CV of 20.65% was calculated for these seven samples which was confirmed 
as statistically significant using / squared analysis. Moreover, results for the two 
transport controls also showed statistically significant intra-individual variation. 
Relatively stable intra-individual variation, with CVs in the range of 7 —10%, has been 
reported by the PICR group in four separate studies (Baria et al 2001; Papworth et cii 
2001; Roberts et a! 1999; Scoff et cii 1999), as well as in other laboratories (Riches et cii 
2001). Validation of the technique at the Dublin Institute of Technology also revealed 
reproducible G2 assay scores in three out of four healthy donors producing CVs between 
4.61% and 5.1%. However, one donor had a CV of 22.9%, which was statistically 
significant (Howe et a! 2005b). An investigation at Ohent University, Belgium, in 
which two individuals gave blood on nine separate occasions over a period of one year 
revealed that intra-individual variability was not significantly different from the inter-
individual variability (Vral et a! 2002) corroborating the findings of other studies 
(Baeyens et cii 2002; Baria et cii 2002). In addition, an individual previously determined 
to be radiosensitive using the 90th percentile cut-off gave radiosensitivity scores in the 
normal range at two subsequent repeat sampling points. A follow-up study conducted 
over a period of three years in which 14 donors were repeatedly sampled, revealed non-
significant variation in three out of the four donors that had multiple sampling (5 - 15 
repeat samples) (Vral et a! 2004). This suggests that there is good reproducibility for 
three out of four of these individuals. 
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Many laboratories have now reached the consensus that a single sample is insufficient 
to ascertain the 02 chromosomal radiosensitivity of an individual and that multiple 
blood sampling of the same individual may be required to make definitive conclusions 
(Bryant et al 2002; Vral et al 2002; Vral et al 2004). Vral et al (2004) speculate that a 
blood sample taken on a single occasion may not be reproducible because the ratio of 
lymphocyte subsets may change with time and blood composition is influenced by 
hormone levels, diet and immune status. Support for this comes from a number of in 
vivo and in vitro studies which demonstrate that hormone levels influence 
radiosensitivity (Kanda and Hayata 1999; Ricoul and Dutrillaux 1991; Ricoul et al 
1997; Roberts et al 1997). In the WRI 2005 Danish trio study, it was suggested that the 
significant intra-individual variation observed in the transport control was caused by 
hormonal changes due to the donor becoming pregnant during the study (Curwen et a! 
2005). Interestingly, analysis of the first five samples received pre-pregnancy revealed 
no significant variation hinting at a hormonal effect due to pregnancy (Curwen et al 
2005). This individual acted as transport control 1 in this study. Subsequent re-
sampling of transport control 1 for this current project, who was not pregnant at any 
stage, revealed statistically significant variation between the seven samples indicating 
that intra-individual variation is more likely to be an intrinsic characteristic of transport 
control 1 and not linked to pregnancy. 
There have been some suggestions that 02 score may be influenced by a transport effect 
(Bryant et al 2002; Roberts et a! 1999; Scott et a! 1999). Although a transportation 
effect cannot be completely discounted, the significant variability of the WRI internal 
assay control, in which blood did not leave the laboratory, suggests that variability may 
be an intrinsic characteristic of all three of the control donors used for this project. 
Further support for the intrinsic nature of intra-individual variation in aberration yields 
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comes from studies which have investigated inter-experimental parameters. When 
multiple cultures are set up from the same blood sample, high levels of assay 
reproducibility have been observed at WRI (Smart et al 2003) and in other laboratories 
(Vral et al 2002). Moreover, multiple sampling of an individual throughout a single day 
has not revealed significant variation (Docherty et a! 2007). Thus, it seems unlikely that 
experimental factors such as irradiation conditions, medium and minor timing 
differences influence variability in chromatid aberration yields observed when an 
individual is sampled on separate occasions. Although there is a paucity of available 
data on individuals with multiple sampling, it is not always the case that when more 
samples are taken the more likely it is that variation becomes significant. For example, 
good reproducibility has been demonstrated in two separate donors following 13 (Smart 
et a! 2003) and 15 samples (Vral et a! 2004). 
As demonstrated in the majority of studies, significant intra-individual variability only 
occurs in a proportion of donors (Smart a a! 2003; Yral et a! 2002; Vral et a! 2004). 
Thus, providing the cohort consists of sufficient numbers then population-based assays 
can still provide valuable information on the relationship between 02 radiosensitivity, 
cancer predisposition and heritability of the G2 radiosensitivity phenotype. In addition, 
02 radiosensitivity scores have been shown to correlate with gene expression level 
(Sims a a! 2007) and adverse radiotherapy response (De Ruyck a a! 2005) which 
demonstrates that the 02 radiosensitivity assay is reliable enough for comparison with 
other endpoints. However, due to the high intra-individual variability observed in all 
three control samples used in this study, the reproducibility of the 02 radiosensitivity 
scores for each of the cancer survivors is open to conjecture. 
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3.4.2 The Relationship between G2 Checkpoint Delay and C2 Chromosomal 
Radiosensitivity in the Internal Assay Control 
Although only four samples were taken from the internal assay control there is a hint 
that 02 to metaphase progression in response to radiation varies within an individual. 
The suggested trend, although not statistically significant, indicates that an increase in 
02 checkpoint delay correlates with a decrease in chromatid aberrations at metaphase. 
This is an interesting finding and multiple sampling of a single individual could confirm 
whether this was a statistical anomaly. It has been postulated that heterogeneity of cell 
cycle progression rather than DNA repair capacity is responsible for the variation in 02 
chromosomal radiosensitivity observed in normal individuals (Palitti et al 1999). These 
limited data set of four samples provide some evidence for this hypothesis. 
3.4.3 The Relationship between G2 Chromosomal Radiosensitivity and G2 
Checkpoint Delay in the Cancer Survivor Group 
It is known that cells have checkpoints which arrest in response to DNA damage and it 
has been postulated that these checkpoints exist to allow time for DNA repair (Weinert 
et al 1994). lonising radiation delivered in the 02 phase of the cell cycle can cause a 
transient ATM-dependent cell cycle arrest which allows time for repair and prevents the 
progression of damaged cells from 02 phase into mitosis (Xu et al 2002). Studies 
employing radiation-induced MIn have revealed that the arrest in 02 is much less 
pronounced in cells from patients with AT than in normal cells (Scott et a! 1 994b; Scott 
and Zampetti-Bosseler 1982; Zampetti-Bosseler and Scott 1981). The hypothesis was 
that a low MIn value represents a deficient checkpoint in which less time is allowed for 
the repair of chromosome damage before the onset of mitosis and thus, higher 
aberration yields would be observed at metaphase (Scoff et a! 2003; Terzoudi and 
Pantelias 1997; Zampetti-Bosseler and Scoff 1981). More recent studies utilising PCC 
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methodology support this idea. The enumeration and classification of 02 and 
metaphase cells following irradiation have revealed that a less efficient 02 checkpoint is 
responsible for the enhanced G2 chromosomal radiosensitivity observed in AT cells 
(Terzoudi et a! 2005) and in normal lymphocytes pre-treated with the benzene 
metabolite hydroquinone (Hatzi et a! 2007). However, investigations of prostate cancer 
(Howe a al 2005a) and BCRA 1 heterozygotes (Febrer a al 2008) have revealed that an 
increase in G2 checkpoint delay is related to increased chromatid gaps and breaks at 
metaphase. Heterozygous females (BRCAJj underwent significantly more delay in 02 
than control females and yet had more chromatid damage at metaphase (Febrer et al 
2008). The authors suggest that the increased levels of chromatid aberrations observed 
in BRCA 1' females may be a result of reduced repair capability but they do not rule out 
the possibility that the 02 checkpoint is less proficient despite the increase in 02 delay 
observed. For example, a key finding of this work was that the number of chromatid 
breaks observed directly in 02 did not differ between BRCA and BRCA' females but 
the reduction of ehromatid damage following G2 to metaphase transition was 32-63% in 
BRCA' females compared to only 13-28% in BRCA' females. The authors propose 
that the reduction in damage from 02 to metaphase is a better endpoint for 
differentiating between radiosensitive and non-radiosensitive groups rather than the 
conventional 02 assay method of observing chromatid aberrations in metaphase which 
show considerable overlap between patient and control populations in most studies. 
Investigations into well characterised mutations in genes such as ATM and BRCA enable 
a fully controlled examination of the role of 02 to metaphase transition in the reduction 
of chromatid damage at metaphase. Although a 02 checkpoint defect has been clearly 
detected in AT patients and linked to their inherent elevated radiosensitivity, less 
substantial evidence exists for a relationship between 02 checkpoint delay and 02 
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chromosomal radiosensitivity in sporadic cancer patients. An increase in the extent of 
MIn has been associated with a decrease in the amount of chromatid damage in a mixed 
population of breast cancer patients and nonnal females following an acute dose of 0.5 
Gy (Scott et al 2003). Moreover, this study revealed less 02 arrest in breast cancer 
patients in comparison to healthy female controls suggesting a putative 02 checkpoint 
defect which may contribute to the enhanced 02 chromosomal radiosensitivity seen in 
approximately 40% of cases. However, the authors proposed that only a very small 
proportion of radiosensitive patients may have a 02 checkpoint deficiency and conclude 
that chromatid aberration frequency and the extent of mitotic inhibition may not be 
causally related. 
Prior to using PCC, an earlier study at WRI investigated the relationship between 02 
checkpoint delay and 02 chromosomal radiosensitivity in survivors of early-onset 
cancer, their spouses and offspring using mitotic inhibition (Curwen, PhD thesis 2007). 
There was no significant correlation between 02 checkpoint delay and chromatid 
aberration frequency. In the present project, chemically-induced PCC was applied to a 
group of 29 childhood and young-adulthood cancer survivors in an attempt to 
investigate any relationship between 02 checkpoint delay and 02 chromosomal 
radiosensitivity. Again, there was no significant correlation between 02 checkpoint 
delay and chromatid aberration frequency. Examination of alternative radiosensitivity 
endpoints such as clonogenic survival have also demonstrated that defective 02 
checkpoints, such as those found in BRCA] mutated cell lines, are not linked to 
radiosensitivity (Xu et a! 2002). The exact causes of the large inter-individual variation 
observed when using the 02 chromosomal radiosensitivity assay have not yet been 
elucidated. Such variation may be a consequence of disparity between individuals in 
the initial yield of chromatid aberrations, differences in DNA repair capacity, and 
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variation in cell cycle control during G2 to M transition, although other explanations and 
influencing factors cannot be ruled out. For example, a recent study at the University of 
St. Andrews provides evidence that inter-individual variation in chromatid break 
frequency may result from differences in the level of topoisomerase Ilci expression 
(Terry ci al 2008). 
An unexpected finding in the Danish cancer survivor cohort, which was not observed in 
the initial attempts at applying the PCC technique, was that a number of samples 
displayed negative 02 checkpoint delay values indicating a greater proportion of 
'metaphase-like' cells in the irradiated sample than in the control sample. A possible 
explanation is that differentiating between 02 and metaphase cells based upon a lack of 
centromeric constriction as seen in other studies (Febrer ei al 2008; Gotoh ci al 1995; 
1-latzi ci al 2007; 1-latzi ci al 2008; Terzoudi ci al 2005) is an imperfect technique. A 
shorter calyculin A incubation of 15 minutes has recently been used to improve the 02 
assay by increasing the mitotic index of blood cultures whilst still resulting in a majority 
of cells with clear centromeric constriction (Shovman el a! 2008). The authors 
suggested that a proportion of cells with 'metaphase-like' morphology and centromeric 
constriction are in fact cells in 02 phase which have been artificially condensed. 
3.4.4 The Influence of Cancer Type on 62 Chromosomal Radiosensitivity and 62 
Checkpoint Delay. 
The effect of cancer type on G2 chromosomal radiosensitivity and 02 checkpoint delay 
was not a key aim of this MSc project. Moreoyer, early-onset cancer accounts for less 
than 2% of all cancers diagnosed in the U.K (Baria ci a! 2002) and thus, comparisons 
between groups of patients with a specific type of early-onset cancer would have, in 
practice, proved difficult. Nonetheless, for the purpose of analysis, cancer type was 
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divided into haematological (Hodgkin's/non-Hodgkin's) and other cancers 
(testis/wilms'/neuroblastoma). As perhaps might be expected, no significant differences 
between the two groups were observed for either 02 Chromosomal Radiosensitivity or 
02 Checkpoint Delay. 
The aim of the over-arching study into the genetic consequences of cancer treatment 
was to investigate the contribution of radiotherapy and/or chemotherapy towards 
adverse health outcomes in the offspring of survivors of cancer (www.gcct.org ). The 
cancer survivors were primarily recruited based on the likelihood of high doses received 
to the gonads, hence, the large proportion of Hodgkin's disease and Non-Hodgkin's 
lymphoma patients in this study. These two malignancies both have a different 
aetiology to breast, colorectal and lung cancer and crucially, are more likely to be 
caused by defects other than DNA damage/repair or cell cycle checkpoint deficiency. 
For example, Hodgkin's lymphoma is caused by a combination of infection with 
Epstein-Barr Virus (Kapatai and Murray 2007), re-arrangement defects in the 
immunological system (Mathas 2007) and genomic alterations (Weniger et al 2006). 
Thus, it is possible that low-penetrance cancer predisposition genes, putatively manifest 
in breast cancer patients as elevated 02 chromosomal radiosensitivity (Scott et al 1999) 
or to a lesser extent decreased 02 delay (Scott et a! 2003), are not discernible in the 
Danish cancer survivor cohort. 
3.4.5 The Influence of Age and Gender upon 02 Chromosomal Radiosensitivity 
and G2 Checkpoint Delay. 
Radiation-induced MIn studies by the PICR group have revealed significant age and 
gender influences. For example, Mln was shown to be significantly greater in female 
than in male controls (Scott et a! 2003) and Mln has been shown to decrease with age 
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(Scott et al I 994b; Scoff et al 2003). Despite MIn declining with age, no relationship 
between age and chromatid aberration frequency has been uncovered (Scott et al 1999). 
Moreover, sex and/or age differences have not been observed when considering 02 
chromosomal radiosensitivity in breast cancer in other laboratories (Baeyens eta! 2005; 
Riches et a! 2001; Scott et a! 1999), other cancers (Baria et a! 2001; De Ruyck et al 
2008; Sanford eta! 1996), common variable immune deficiency (Aghamohammadi et a! 
2008) or in clinically normal donors (Borgmann et a! 2007; Cadwell a a! 2008; 
Papworth eta! 2001). Interestingly, Docherty a a! (2007) found that G2 chromosomal 
radiosensitivity decreased with age but only when chromatid gaps smaller than the 
width of a chromatid were included in the analysis. When breaks (discontinuities larger 
than the width of a chromatid) were considered alone, as is the case in many 
laboratories, no significant correlation was observed (Docherty a a! 2007). The 
influence of age has become apparent in head and neck cancer studies with patients in 
the youngest age groups showing enhanced sensitivity over control groups (De Ruyck et 
a! 2008; Papworth a a! 2001), although no significant correlation between age and 
chromatid aberration frequency has been established (De Ruyck et a! 2008). 
Environmental influences, such as smoking and alcohol, predominate in the older group 
indicating a lower genetic component compared to the youngest patients. Hence, late-
onset cases had similar G2 scores to controls within the 45 and over age group 
(Papworth eta! 2001). In this study of childhood and young-adulthood cancer survivors 
no significant age or gender effects were found when comparing (12 checkpoint delay 
between different sub-groups or when investigating the relationship between radiation-
induced G2 checkpoint delay and 02 chromatid aberration frequency. 
3.4.6 Conclusion 
In conclusion, the results of this study have shown that inter-individual variation in 02 
chromosomal radiosensitivity is not driven by variation in 02 checkpoint delay, at least 
in this group of cancer survivors. In addition, the results have demonstrated that age, 
gender and cancer type have no significant influence upon either cell cycle delay or G2 
chromosomal radiosensitivity. 
3.4.7 Limitations 
As applied in this study, the PCC technique appears to have a number of limitations 
including difficulty in scoring damage directly in PCC-G2 cells, doubts over the 
accuracy and validity of cell cycle categorisation and limitations due to intra-individual 
variability in both 02 chromosomal radiosensitivity and G2 checkpoint delay. For these 
reasons it was difficult to establish whether the PCC technique has provided useful 
information on the impact of 02 to metaphase transition upon the levels of chromatid 
damage observed in metaphase. However, other studies have shown that the PCC 
technique can add considerable value to the G2 radiosensitivity assay with only a minor 
change to the already established protocol (Febrer et al 2008; Shovman et a! 2008; 
Terzoudi et al 2005). 
In normal donors, an increased chromatid aberration frequency was associated with a 
decrease in mitotic delay induced by 0.02 Gy but not when a dose of 0.3 Gy was used to 
induce delay (Pretazzoli et a! 2000). The authors speculate that a saturation effect exists 
at higher doses. Further evidence for a saturation effect at even higher doses is that the 
extent of 02 delay is independent of dose in the range 1 - 10 Gy (Xu et a! 2002). One 
possible explanation for the negative results of this study is that the X-ray dose 
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employed in the 02 chromosomal assay is too high to uncover subtle differences in 02 
checkpoint delay. 
3.4.8 Scope for Future Work 
Further experiments could be used to obtain a dose response curve to pinpoint the dose 
that provides best discrimination for uncovering a possible relationship between 02 
chromosomal radiosensitivity and 02 checkpoint delay. Results from this study make it 
difficult to ascertain whether the PCC technique has any advantages over MIn in 
measuring the extent of 02 checkpoint delay. The technique of MIn can be carried out 
quickly without any modification to the 02 assay and uses the same slides which are 
used for chromatid aberration analysis making it less expensive and more efficient than 
PCC analysis. In addition, it is possible to train the Metafer software to automatically 
scan and score mitotic indices. It would be of interest to compare 02 checkpoint delay 
values obtained using PCC with the conventional method of Mm. In this cohort, the 
intra-individual variation was too variable to assign a definitive score of 02 
chromosomal radiosensitivity on an individual basis and the same level of caution 
should be applied when assigning a score of 02 checkpoint delay, especially after a 
single sample. A well-controlled study on a small number of normal individuals with 
repeated sampling for both G2 checkpoint delay and 02 chromosomal radiosensitivity 
may be needed to tease out any causative relationship. 
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APPENDIX A: WRI CONSENT FORM 
Form: GENL4B-óvI 
Jan 2007 
Firsi Issue 
CONSENT FORM FOR BLOOD SAMPLES FOR IN VITRO STUDIES OF EXPOSURE TO 
RADIATION 
I am willing to provide a blood sample. 
I understand that the sample will be used for research studies associated with in vitro exposure to 
radiation. I understand any information pertaining to the sample will be protected by the principles of 
confidentiality and will conform to the Data Protection Act (1998) and the Human Tissue Act (2004). 
Signed - ....................................................Date- ....................................... 
Name - .................................(first name) .................................(family name) 
(please print) 
Dateof Birth - .......................................................Gender .................................. 
Are you a smoker? 	 Yes 	 No 	 Ex-snioker 
Have you ever had any radiotherapy/chemotherapy? 
	
Yes 	 No 
Comments 
Al 
APPENDIX B: ZEISS AXIOPLAN 2 IMAGING MICROSCOPE 
WITH A MARZHAUSER MOTORIZED SCANNING STAGE 
I-ti' 
I,. 
ft 
APPENDIX C: QUESTIONNAIRE FOR DANISH FAMILIES 
(modified to fit page layout) 
QUESTIONNAIRE 
Indication of Genetic Damage Transmitted to Children of 
Danish Survivors of Childhood Cancer 
- A Feasibility Blood Collection Study 
[cI 
Institute of Cancer Epidemiology 
Danish Cancer Society 
Strandboulevarden 49 
DK-2100 Copenhagen 0 
Study no.: 	 Date of interview: 
CI 
1. Basic information 
MF 
1.lSex 	 1-1-1 
Year 
1.2 Age 	 I_I_I 
2. Cancer in the family 
Yes No Not 
sure 
2.1 Has anyone in your nearest biological family had cancer? 
(Parents, grandparents, siblings, children, parent's siblings; i.e. aunts and uncles, but 
not adopted children, stepfamily or family in-laws) 
2.2 If yes, please specifr 
Family member I Type of cancer/Not sure 
	 lCD-S 
C2 
3. Smoking habits 
Yes No 
Yes No 
I-I-I 
Age 
Age 
Year 
I-I-I 
3.1 Are you a current smoker? 
(at least 1 cigarette per day in 6 months or cigar/pipe) 
3.2 Have you previously been a current smoker? (defined as above) 
3.3 How much do/did you smoke in average per day/weekImontb? 
Number of cigarettes 
Per day 
Per week 
Per month 
3.4 Age at start of smoking? 
3.5 Age at quitting, if former smoker? 
3.6 Total years of daily smoking? 
[*1 
4. Medications 
4.1 Do you currently use any form of medication? 
We ask you about prescription and over-the counter drugs as well as alternative 
medicine. 	 Yes No 
I_Li 
If yes, please specify the name of the drug(s), duration of use as well as the indication 
Drug name 	 Duration of use in 	 Indication 
months (m)/years (y) 
4.2 Have you previously received large doses of chemotherapy or similar drugs 
due to serious illness? 
Yes No 
Drug name 	 Duration of use in 	 Indication 
months (m)/years (y) 
C4 
5. Use of Hormones (women only) 
Yes No 
5.1 Do you use oral contraceptives? 
	 I_I__I 
If yes, please speci' the name of the drug(s) and duration of use 
Drug name 	 Duration of use in months (m)Iyears (y) 
Yes No 
5.2 Do you use any other type of hormones, such as estrogens and/or 
progesterones? 
If yes, please specify the name of the drug(s), duration of use and type of hormones 
Drug name 	 Duration of use in 	 Type of hormones 
months (m)/years (y) 
Estrogen only, progesterone only, combination pills, others (please specif') 
C5 
APPENDIX D: CONSENT FORM AND INFORMATION FOR 
DANISH FAMILIES 
Informed Consent 
Indication of Genetic Damage Transmitted to the Children of 
Danish Survivors of Childhood Cancer 
- A Feasibility Blood Collection Study 
I have read the information brochure, and I hereby confirm that I agree to 
participate in the study. 
Furthermore, I give permission to having my and my child/children's blood drawn 
I understand that participation in the study is entirely voluntary and that I can withdraw 
my and my child/children's commitment without giving any explanation. 
Do you allow your blood sample to be at stored at the Institute of Cancer Biology, 
Danish Cancer Society, Copenhagen, and to be used in future studies on childhood 
cancer after renewed approval from the Danish Ethical Committee? 
O Yes 
ONo 
Do you allow your child/children's blood sample to be at stored at the Institute of 
Cancer Biology, Danish Cancer Society, Copenhagen, and to be used in future studies 
on childhood cancer after renewed approval from the Danish Ethical Committee? 
O Yes 
ONo 
Date: 
Name: 
Signature: 
ra 
Institute of Cancer Epidemiology 
banish Cancer Society 
Strandboulevarden 49 
bK-2100 Copenhagen, benniark 
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APPENDIX E: THE WRI G2 RADIOSENSITIVITY SCORE SHEET 
Code:- 	 Irradiated 	 Control 	 Microscope no.:- 
	 Scorer:- 
Date:- 
a 
- 
- 
- 
- 
- 
El. 
a 
- 
- 
El 
APPENDIX F: THE Will PCC SCORE SHEET 
24 	 PCC/PCC 	 kC TEST G2 & PCC II 
won. On P_1v1 
Ang 3005 
flr.t Z..ne 
PCC cell proportions 
rwatsated 
24 
Slidename 	 erchoy Ctngfly 	 Chngnat. NCelle Undefined Rejected 
XC TEST 02 & P Adan 
	 AUiu 	 23/09/05 	 460 	 432 	 4 
floC.111fl 02 Slat 01 S Xntflnlaa 
1 	 1 1 0 0 0 0 	 0 
2 	 2 0 1 0 0 0 	 0 
3 	 3 0 1 0 0 0 	 0 
4 	 4 0 1 0 0 0 	 0 
5 	 5 0 1 0 0 0 	 0 
6 	 6 0 1 0 0 0 	 0 
7 	 7 0 1 0 0 0 	 0 
0 	 8 1 0 0 0 0 	 0 
9 	 9 0 1 0 0 o 	 0 
10 	 10 0 1 0 0 0 	 0 
11 	 13 1 0 0 0 0 	 0 
12 	 14 1 0 0 0 0 	 0 
13 	 15 0 1 0 0 0 	 0 
14 	 16 0 1 0 0 0 	 0 
15 	 11 0 1 0 0 0 	 0 
16 	 18 0 1 0 0 0 	 0 
17 	 19 0 1 0 0 0 	 0 
18 	 21 0 1 0 0 0 	 0 
19 	 22 0 1 0 0 0 	 0 
20 	 23 0 1 0 0 0 	 0 
21 	 24 0 1 0 0 0 	 0 
22 	 25 0 1 0 0 0 	 0 
23 	 27 0 1 0 0 0 	 0 
24 	 28 0 1 0 0 0 	 0 
4 20 0 0 0 	 0 
Signatare of 	 Scorer 	 ------------------------------------ Date 	 ............... 
M.tasysten.s Metafert MSearcIWTL 	 I 0W02100 00:10:22 1W TEST 02 & PCC II 
Fl 
